Regenerative Medical Technology (RMTG) POS AM 22 Aug 24 Prospectus update (post-effective amendment) Financial data

Document And Entity Information

Document And Entity Information	6 Months Ended
	Jun. 30, 2024
Document Information Line Items
Entity Registrant Name	Meso Numismatics, Inc.
Document Type	POS AM
Amendment Flag	true
Amendment Description	On January 2, 2024, we filed with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-1 (File No. 333-276343) (the “Registration Statement”), to register for resale by the selling shareholder, the offer and sale of up 5,000,000 shares of common stock. The Registration Statement was declared effective by the SEC on January 10, 2024.This Post-Effective Amendment No. 1 (the “Post Effective Amendment”) to the Registration Statement is being filed pursuant to the undertakings in the Registration Statement to update and supplement the information contained in the Registration Statement, which was previously declared effective by the SEC. No additional securities are being registered under this Post Effective Amendment. All applicable registration fees were paid at the time of the Registration Statement.This Post Effective Amendment is being filed to (i) update the contents of the prospectus contained in the Registration Statement pursuant to Section 10(a)(3) of the Securities Act of 1933, as amended, in respect of the continuous offering pursuant to Rule 415 of shares of our common stock, (ii) incorporate certain information from our Annual Report on Form 10-K for the year ended December 31, 2023 that was filed with the SEC on April 15, 2024, and (iii) incorporate certain information from our Form 10-Q for the three and six months ended June 30, 2024, filed with the SEC on August 14, 2024.
Entity Central Index Key	0001760026
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Incorporation, State or Country Code	NV

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2024	Dec. 31, 2023	[1]	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 617,093	$ 530,540		$ 1,645,185
Accounts receivable	24,188	23,956		49,766
Inventory	6,680
Prepaid expenses	38,610	20,500
Total current assets	686,571	574,996		1,694,951
Property and equipment, net	360,341	359,303		186,269
Other assets	7,264	5,568		5,568
Intangible assets, net	207,774	256,544		354,084
Right of use asset, net	108,158	2,714		33,963
Goodwill	1,679,978	1,679,978		5,805,438
Total assets	3,050,085	2,879,103		8,080,273
Current liabilities
Accounts payable and accrued liabilities	562,188	421,334		245,463
Accrued interest	8,130,464	6,597,422		4,657,530
Customer advances	372,860	2,000		10,450
Derivative liability	4,352	2,146		6,944
Lease liability, current portion	76,092	2,714		32,568
Notes payable, net	17,270,761	15,223,519		7,046,666
Total current liabilities	26,416,717	22,249,135		11,999,621
Long term liabilities
Lease liability, net of current portion	32,066			1,395
Convertible notes payable, net of discount	39,981	35,023		37,419
Notes payable, net of discount	2,386,664	2,382,648		8,016,330
Total liabilities	28,883,228	24,674,605		20,062,565
Stockholders’ deficit
Additional paid in capital	40,181,074	40,181,074		40,180,669
Accumulated deficit	(66,027,771)	(61,990,131)		(52,176,465)
Total stockholders’ deficit	(25,833,143)	(21,795,503)		(11,982,292)
Total liabilities and stockholders’ deficit	3,050,085	2,879,103		8,080,273
Related Party
Long term liabilities
Notes payable-related parties	7,800	7,800		7,800
Series AA Preferred Stock
Stockholders’ deficit
Preferred stock value	1,050	1,050		1,050
Series DD Preferred Stock
Stockholders’ deficit
Preferred stock value	10	10		10
Common Stock
Stockholders’ deficit
Common stock value	$ 12,494	$ 12,494		$ 12,444
[1] Derived from audited information

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares	Jun. 30, 2024	Dec. 31, 2023	[1]	Dec. 31, 2022
Series AA Preferred Stock
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001		$ 0.001
Preferred stock, shares authorized	1,050,000	1,050,000		1,050,000
Preferred stock, shares issued	1,050,000	1,050,000		1,050,000
Preferred stock, shares outstanding	1,050,000	1,050,000		1,050,000
Series DD Preferred Stock
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001		$ 0.001
Preferred stock, shares authorized	10,000	10,000		10,000
Preferred stock, shares issued	9,870	9,870		9,422
Preferred stock, shares outstanding	9,870	9,870		9,422
Common Stock
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001		$ 0.001
Common stock, shares authorized	6,500,000,000	6,500,000,000		6,500,000,000
Common stock, shares issued	12,493,938	12,493,938		12,443,938
Common stock, shares outstanding	12,493,938	12,493,938		12,443,938
[1] Derived from audited information

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenue	$ 793,329	$ 361,359	$ 1,610,363	$ 1,147,557	$ 2,409,953	$ 1,530,223
Cost of revenue	266,445	107,535	514,488	356,932	734,285	653,256
Gross profit	526,884	253,824	1,095,875	790,625	1,675,668	876,967
Operating expenses
Advertising and marketing	97,175	114,811	241,458	256,448	476,989	317,796
Professional fees	253,008	255,412	501,390	464,783	752,277	886,651
Officer compensation	22,500	22,500	45,000	45,000	90,000	90,000
Depreciation and amortization expense	82,971	57,875	159,543	114,503	310,102	152,739
Investor relations	23,174	2,250	46,442	4,500	9,000	190,382
General and administrative	262,036	231,817	421,127	410,443	752,527	424,258
Total operating expenses	740,863	684,665	1,414,961	1,295,677	2,390,894	2,061,826
Other income (expense)
Interest expense	(1,861,931)	(1,600,380)	(3,716,348)	(3,200,806)	(6,491,538)	(4,403,774)
Gain on derivative financial instruments	(708)	998	(2,206)	2,925	4,798	13,498
Other income					2,463
Gain on extinguishment of debt					1,511,297
Impairment of goodwill					(4,125,460)
Gain on settlement of debt				2,463
Net loss	$ (2,076,620)	$ (2,030,223)	$ (4,037,640)	$ (3,700,470)	(9,813,666)	(5,506,822)
Loss from continuing operations					(9,813,666)	(5,575,135)
Discontinued operations:
Gain (loss) on sale of discontinued operations						68,313
Income (loss) from discontinued operations						$ 68,313
Basic and diluted earnings (loss) per share from:
Continuing operations (in Dollars per share)					$ (0.79)	$ (0.46)
Discontinued operations (in Dollars per share)						0.01
Net loss per common share, basic (in Dollars per share)	$ (0.17)	$ (0.16)	$ (0.32)	$ (0.3)	$ (0.79)	$ (0.45)
Weighted average number of common shares outstanding, basic (in Shares)	12,493,938	12,443,938	12,493,938	12,443,938	12,447,089	12,219,502

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) - $ / shares	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Net loss per common share, diluted	$ (0.17)	$ (0.16)	$ (0.32)	$ (0.30)	$ (0.79)	$ (0.45)
Weighted average number of common shares outstanding, Diluted	12,493,938	12,443,938	12,493,938	12,443,938	12,447,089	12,219,502

Consolidated Statements of Stoc

Consolidated Statements of Stockholders’ Deficit (Unaudited) - USD ($)	Preferred Stock Series AA	Preferred Stock Series DD	Common Stock	Additional Paid In Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2021	$ 1,050	$ 10	$ 12,086	$ 39,899,491	$ (46,669,643)	$ (6,757,006)
Balance (in Shares) at Dec. 31, 2021	1,050,000	9,422	12,085,125
Issuance of common stock for services			$ 358	29,642		30,000
Issuance of common stock for services (in Shares)			358,813
Issuance of preferred series DD for services-related party				251,536		251,536
Issuance of preferred series DD for services-related party (in Shares)		448
Net loss					(5,506,822)	(5,506,822)
Balance at Dec. 31, 2022	$ 1,050	$ 10	$ 12,444	40,180,669	(52,176,465)	(11,982,292)
Balance (in Shares) at Dec. 31, 2022	1,050,000	9,870	12,443,938
Net loss					(3,700,470)	(3,700,470)
Balance at Jun. 30, 2023	$ 1,050	$ 10	$ 12,444	40,180,669	(55,876,935)	(15,682,762)
Balance (in Shares) at Jun. 30, 2023	1,050,000	9,870	12,443,938
Balance at Dec. 31, 2022	$ 1,050	$ 10	$ 12,444	40,180,669	(52,176,465)	(11,982,292)
Balance (in Shares) at Dec. 31, 2022	1,050,000	9,870	12,443,938
Issuance of common stock for services			$ 50	405		455
Issuance of common stock for services (in Shares)			50,000
Net loss					(9,813,666)	(9,813,666)
Balance at Dec. 31, 2023	$ 1,050	$ 10	$ 12,494	40,181,074	(61,990,131)	(21,795,503)	[1]
Balance (in Shares) at Dec. 31, 2023	1,050,000	9,870	12,493,938
Balance at Mar. 31, 2023	$ 1,050	$ 10	$ 12,444	40,180,669	(53,846,712)	(13,652,539)
Balance (in Shares) at Mar. 31, 2023	1,050,000	9,870	12,443,938
Net loss					(2,030,223)	(2,030,223)
Balance at Jun. 30, 2023	$ 1,050	$ 10	$ 12,444	40,180,669	(55,876,935)	(15,682,762)
Balance (in Shares) at Jun. 30, 2023	1,050,000	9,870	12,443,938
Balance at Dec. 31, 2023	$ 1,050	$ 10	$ 12,494	40,181,074	(61,990,131)	(21,795,503)	[1]
Balance (in Shares) at Dec. 31, 2023	1,050,000	9,870	12,493,938
Net loss					(4,037,640)	(4,037,640)
Balance at Jun. 30, 2024	$ 1,050	$ 10	$ 12,494	40,181,074	(66,027,771)	(25,833,143)
Balance (in Shares) at Jun. 30, 2024	1,050,000	9,870	12,493,938
Balance at Mar. 31, 2024	$ 1,050	$ 10	$ 12,494	40,181,074	(65,951,151)	(25,756,523)
Balance (in Shares) at Mar. 31, 2024	1,050,000	9,870	12,493,938
Net loss					(2,076,620)	(2,076,620)
Balance at Jun. 30, 2024	$ 1,050	$ 10	$ 12,494	$ 40,181,074	$ (66,027,771)	$ (25,833,143)
Balance (in Shares) at Jun. 30, 2024	1,050,000	9,870	12,493,938
[1] Derived from audited information

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended			12 Months Ended
	Jun. 30, 2024		Jun. 30, 2023	Dec. 31, 2023		Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (4,037,640)		$ (3,700,470)	$ (9,813,666)		$ (5,506,822)
Non-cash adjustments to reconcile net loss to net cash:
Amortization of debt discount	2,056,217		1,531,096	3,059,914		1,756,764
Depreciation and amortization expense	159,543		114,503	310,102		152,739
Loss (gain) from changes in derivative liability fair values	2,206		(2,925)	(4,798)		(13,498)
Common shares issued for services				455		10,000
Gain from settlement of debt			(2,463)	(2,463)
Gain on extinguishment of debt				(1,511,297)
Impairment of goodwill	4,125,460			4,125,460
Changes in operating assets and liabilities:
Accounts receivable	(232)		(1,495)	25,810		(32,510)
Prepaid expenses	(18,110)			(20,500)
Inventory	(6,680)
Other asset	(1,696)
Accounts payable and accrued liabilities	2,044,755		1,661,816	3,411,783		2,517,791
Cash used for operating activities-continuing operations				(419,200)		(1,183,849)
Depreciation discontinued operations						1,400
Gain (loss) on discontinued operations						68,313
Cash provided (used) for operating activities-discontinued operations						69,713
CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES	198,364		(399,938)	(419,200)		(1,114,136)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment	(111,811)		(10,207)	(385,596)		(198,428)
CASH USED BY INVESTING ACTIVITIES	(111,811)		(10,207)	(385,596)		(198,428)
CASH FLOWS FROM FINANCING ACTIVITIES
Principal payment on debt			(9,850)	(9,850)		(20,776)
Consideration paid to note holder				(300,000)
CASH USED BY FINANCING ACTIVITIES			(9,850)	(309,850)		(20,776)
Net increase (decrease) in cash	86,553		(419,995)	(1,114,645)		(1,333,340)
Cash, beginning of period	530,540	[1]	1,645,185	1,645,185		2,978,525
Cash, end of period	617,093		1,225,190	530,540	[1]	1,645,185
Cash paid for income taxes
Cash paid for interest				446		283
NON-CASH FINANCING ACTIVITIES:
Stock issued through stock payable				455		271,536
Right of use asset financed through payable						62,903
Net loss from continuing operations				$ (9,813,666)		$ (5,575,135)
[1] Derived from audited information

Organization and Description of

Organization and Description of Business	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Organization and Description of Business [Abstract]
ORGANIZATION AND DESCRIPTION OF BUSINESS	NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS Organization and History Meso Numismatics, Inc. (the “Company”) was originally organized under the laws of Washington State in 1999, as Spectrum Ventures, LLC to develop market and sell VOIP (Voice over Internet Protocol) services. In 2002, the Company changed its name to Nxtech Wireless Cable Systems, Inc. In August 2007, the Company changed its name to Oriens Travel & Hotel Management Corp. In November 2014, the Company changed its name to Pure Hospitality Solutions, Inc. On November 16, 2016, the Company entered into an Agreement and Plan of Merger between the Company and Meso Numismatics Corp. (“Meso”), a Florida corporation. The acquisition of Meso was to support the Company’s overall mission of specializing in ventures related to Central America and the Latin countries of the Caribbean; not limited to tourism. Meso was a small but scalable numismatics operation that the Company leveraged for low-cost cost revenues and product marketing. The Company maintained an online store with eBay (www.mesocoins.com) and participated in live auctions with major companies such as Heritage Auctions, Stacks Bowers Auctions and Lyn Knight Auctions. The acquisition was completed on August 4, 2017, following the Company issuance of 25,000 shares of Series BB preferred stock to Meso to acquire one hundred (100%) percent of Meso’s common stock. The Company accounted for the acquisition as common control, as Melvin Pereira, the CEO and principal shareholder of the Company controlled, operated and owned both companies. On November 16, 2016, the date of the Merger Agreement and June 30, 2017, the date of the Debt Settlement Agreement, Melvin Pereira, CEO of Pure Hospitality Solutions, owned 100% of the stock of Meso. Pure Hospitality Solutions, Inc. and Meso first came under common control on June 30, 2017. On September 4, 2017, the Company decided to suspend its booking operations, Oveedia, to focus on continuing to build Meso, its numismatic business. The Company did, however, use its footprint within the Latin American region to expand the Company at a much quicker rate. In September 2018, the Company changed its name to Meso Numismatics, Inc. and FINRA provided a market effective date and the new ticker symbol MSSV became effective on October 16, 2018. On July 2, 2018, the Board of Directors authorized and shareholders approved a 1-for-1,000 reverse stock split of the Company’s issued and outstanding shares of common stock held by the holders of record. On August 18, 2021, the Company completed its acquisition of Global Stem Cells Group Inc., through a Stock Purchase Agreement acquiring all the outstanding capital stock of Global Stem Cells Group Inc. and paid the purchase price of a total of 1,000,000 shares of Series AA Preferred Stock in the Company, 8,974 shares of Series DD Preferred Stock in the Company and $225,000 USD (the final payment of $50,000 was made on July 2, 2021). Pursuant to the terms of the Fifth Post Closing Amendment along with the completion of the acquisition of Global Stem Cells Group Inc., the issuance of the 1,000 shares of the Company’s Series CC Convertible Preferred Stock to Lans Holdings Inc. was terminated and replaced with a cash payment as consideration. The Company paid Lans Holdings Inc., by delivery in escrow, an amount equal to USD $8,200,000, which Cash Payment was used by Lans Holdings Inc. for the repurchase of all of its shares of common stock from its common shareholders. On November 3, 2021, the Company paid $8,200,000 in cash to an escrow account set up by Lans Holdings Inc. On October 28, 2022, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Subsidiary with our prior officer and director, Mr. Melvin Pereira, pursuant to which we agreed to sell Mr. Pereira 100% of our interest in Meso. In exchange, Mr. Pereira has agreed to assume all of the liabilities of Meso, provide whatever financial and other materials needed by us to prepare and complete our financial statements for reporting purposes, and to not disparage our company. The Company reclassified $68,313 of liabilities outstanding resulting in a gain on discontinued operations at December 31, 2022. Description of Business As a result of this transaction, the Company is no longer engaged in the sale of coins, paper currency, bullion and medals and it has moved into what is believed to be a more lucrative opportunity for the Company - the operations of Global Stem Cell Group. The Company believes stem cell therapy is becoming an increasingly effective clinical solution for treating conditions that traditional or conventional medicine only offers within palliative care and pain management. The Company works with doctors and their staff to provide products, solutions, equipment, services, and training to help them be successful in the application of Stem Cell Therapies. The Company combines solutions from extensive clinical research with the manufacturing and commercialization of viable cell therapy and immune support related products that it believes will change the course of traditional medicine around the world forever. The Company’s revenue comes directly from the training and the seminars, from the resale of these kits, products, and equipment, services, from patient procedures, and from the reoccurring application of the Company’s process using the kits and solutions it provides.	NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS Organization and History Meso Numismatics, Inc. (the “Company”) was originally organized under the laws of Washington State in 1999, as Spectrum Ventures, LLC to develop market and sell VOIP (Voice over Internet Protocol) services. In 2002, the Company changed its name to Nxtech Wireless Cable Systems, Inc. In August 2007, the Company changed its name to Oriens Travel & Hotel Management Corp. In November 2014, the Company changed its name to Pure Hospitality Solutions, Inc. On November 16, 2016, the Company entered into an Agreement and Plan of Merger between the Company and Meso Numismatics Corp. (“Meso”). The acquisition of Meso is to support the Company’s overall mission of specializing in ventures related to Central America and the Latin countries of the Caribbean; not limited to tourism. Meso is a small but scalable numismatics operation that the Company can leverage for low-cost cost revenues and product marketing. Meso Numismatics, Inc. maintains an online store with eBay (www.mesocoins.com) and participates in live auctions with major companies such as Heritage Auctions, Stacks Bowers Auctions and Lyn Knight Auctions. The acquisition was complete on August 4, 2017 following the Company issuance of 25,000 shares of Series BB preferred stock to Meso to acquire one hundred (100%) percent of Meso’s common stock. The Company accounted for the acquisition as common control, as Melvin Pereira, the CEO and principal shareholder of the Company controlled, operated and owned both companies. On November 16, 2016, the date of the Merger Agreement and June 30, 2017, the date of the Debt Settlement Agreement, Melvin Pereira, CEO of Pure Hospitality Solutions, owned 100% of the stock of Meso Numismatics, Inc. Pure Hospitality Solutions, Inc. and Meso Numismatics, Inc. first came under common control on June 30, 2017. On September 4, 2017, the Company decided to suspend its booking operations, Oveedia, to focus on continuing to build its numismatic business, Meso Numismatics. Inc. The Company did, however, use its footprint within the Latin American region to expand Meso Numismatics, Inc. at a much quicker rate. In September 2018, the Company changed its name to Meso Numismatics, Inc. and FINRA provided a market effective date and on September 26, 2018, the new ticker symbol MSSV became effective on October 16, 2018. On July 2, 2018, the Board of Directors authorized and shareholders approved a 1-for-1,000 reverse stock split of its issued and outstanding shares of common stock held by the holders of record. The prior year financials have been changed to reflect the 1-for-1,000 reverse stock split. On August 18, 2021, Meso Numismatics, Inc., completed its acquisition of Global Stem Cells Group Inc., through a Stock Purchase Agreement acquiring all the outstanding capital stock of Global Stem Cells Group Inc and paid the purchase price of a total of 1,000,000 shares of Series AA Preferred Stock in the Company, 8,974 shares of Series DD Preferred Stock in the Company and $225,000 USD (the final payment of $50,000 was made on July 2, 2021). Pursuant to the terms of the Fifth Post Closing Amendment along with the completion of the acquisition of Global Stem Cells Group Inc., the issuance of the 1,000 shares of the Company’s Series CC Convertible Preferred Stock to Lans Holdings Inc. was terminated and replaced with a cash payment as consideration. The Company paid Lans Holdings Inc., by delivery in escrow, an amount equal to USD $8,200,000, which Cash Payment was used by Lans Holdings Inc. for the repurchase of all of its shares of common stock from its common shareholders. On November 3, 2021, the Company paid $8,200,000 in cash to an escrow account set up by Lans Holdings Inc. On October 28, 2022, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Subsidiary with our prior officer and director, Mr. Melvin Pereira, pursuant to which we agreed to sell Mr. Pereira 100% of our interest in Meso Numismatics Corp., a Florida corporation. In exchange, Mr. Pereira has agreed to assume all of the liabilities of Meso Numismatics, provide whatever financial and other materials needed by us to prepare and complete our financial statements for reporting purposes, and to not disparage our company. The Company reclassified $68,313 of liabilities outstanding resulting in a gain on discontinued operations at December 31, 2022. Description of Business As a result of this transaction, the Company is no longer engaged in the sale of coins, paper currency, bullion and medals and it has moved into what is believed to be a more lucrative opportunity for the Company - the operations of Global Stem Cell Group. The Company believes stem cell therapy is becoming an increasingly effective clinical solution for treating conditions that traditional or conventional medicine only offers within palliative care and pain management. The Company works with doctors and their staff to provide products, solutions, equipment, services, and training to help them be successful in the application of Stem Cell Therapies. The Company combines solutions from extensive clinical research with the manufacturing and commercialization of viable cell therapy and immune support related products that it believes will change the course of traditional medicine around the world forever. The Company’s revenue comes directly from the training and the seminars, from the resale of these kits, products, and equipment, services, and from the reoccurring application of the Company’s process using the kits and solutions it provides.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Summary of Significant Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation and Basis of Presentation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Global Stem Cells Group Inc. (since August 18, 2021) and Cellular Hope Institute, wholly-owned subsidiary of Global Stem Cells Group Inc. These condensed consolidated financial statements have been prepared and, in the opinion of management, contain all the adjustments (consisting of those of a normal recurring nature) considered necessary to present fairly the consolidated financial position and the consolidated statements of income and consolidated cash flows for the periods presented in conformity with generally accepted accounting principles for interim consolidated financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X, Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America. Operating results for the three months ended March 31, 2024 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2024. It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2023, filed on April 15, 2024, which can be found at www.sec.gov. All significant intercompany transactions have been eliminated in consolidation. Use of Estimates in Financial Statement Presentation The preparation of these financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The significant estimates included in these financial statements are associated with accounting for the goodwill, derivative liability, valuation of preferred stock, and for the valuation of assets and liabilities in business combination. Reclassifications Certain amounts for the prior year have been revised or reclassified to conform to the current year presentation. No change in net loss resulted from these reclassifications. Cash and Cash Equivalents The Company considers all highly liquid accounts with original maturities of three months or less to be cash equivalents. At June 30, 2024 and December 31, 2023, all of the Company’s cash was deposited in major banking institutions. There were no cash equivalents as of June 30, 2024 and December 31, 2023. Our cash balances at financial institutions may exceed the Federal Deposit Insurance Company’s (FDIC) insured limit of $250,000 from time to time. Accounts Receivable Accounts receivable are recorded at original invoice amount less an allowance for uncollectible accounts that management believes will be adequate to absorb estimated losses on existing balances. Management estimates the allowance based on collectability of accounts receivable and prior bad debt experience. Accounts receivable balances are written off against the allowance upon management’s determination that such accounts are uncollectible. Recoveries of accounts receivable previously written off are recorded when received. Management believes that credit risks on accounts receivable will not be material to the financial position of the Company or results of operations. The allowance for doubtful accounts was $0 and $0 as of June 30, 2024 and December 31, 2023, respectively. Intangible Assets Intangible assets with finite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are not amortized, but are tested for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. No impairment was recognized for the three months ended June 30, 2024 and the year ended December 31, 2023. Lease Accounting The Company leases office space and clinical space under a lease arrangement. These properties are generally leased under non-cancelable agreements that contain lease terms in excess of twelve months on the date of entry as well as renewal options for additional periods. The agreements, which have been classified as operating leases, generally provide for base minimum rental payment, as well non-lease components including insurance, taxes, maintenance, and other common area costs. At the lease commencement date, the Company recognizes a right-of-use asset and a lease liability for all leases, except short-term leases with an original term of twelve months or less. The right-of-use asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease. The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any prepayments to the lessor and initial direct costs such as brokerage commissions, less any lease incentives received. All right-of-use assets are periodically reviewed for impairment in accordance with standards that apply to long-lived assets. The lease liability is initially measured at the present value of the lease payments, discounted using the rate implicit in the contract if available or an estimate of our incremental borrowing rate for a collateralized loan with the same term as the underlying lease. The discount rates used for the initial measurement of lease liabilities as of the date of entry were based on the original lease terms. Lease payments included in the measurement of lease liabilities consist of (i) fixed lease payments for the non-cancelable lease term, (ii) fixed lease payments for optional renewal periods where it is reasonably certain the renewal option will be exercised, and (iii) variable lease payments that depend on an underlying index or rate, based on the index or rate in effect at lease commencement. Certain real estate lease agreements require payments for non-lease costs such as utilities and common area maintenance. The Company has elected an accounting policy to not separate implicit components of the contract that may be considered non-lease related. Lease expense for operating leases consists of the fixed lease payments recognized on a straight-line basis over the lease term plus variable lease payments as incurred. The lease payments are allocated between a reduction of the lease liability and interest expense. Depreciation of the right-of-use asset for operating leases reflects the use of the asset on straight-line basis over the expected term of the lease. Goodwill We test our reporting unit for impairment annually at year end or more frequently if events or circumstances indicate it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the carrying amount of a reporting unit exceeds its estimated fair value, we record an impairment loss based on the difference between fair value and carrying amount of the reporting unit, not to exceed to the associated carrying amount of goodwill. (see Note 11 for detail of goodwill). Derivative Instruments The derivative instruments are accounted for as liabilities, the derivative instrument is initially recorded at its fair market value and is then re-valued at each reporting date, with changes in fair value recognized in operations for each reporting period. The Company uses the Monte Carlo option pricing model to value the derivative instruments. Revenue Recognition The Company recognizes revenue from the sale of products under ASC 606 by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. The Company recognizes revenue when it satisfies a performance obligation by transferring control over a product to a customer or services are provided. Revenue is measured based on the consideration the Company receives in exchange for those products. Income Taxes The Company uses the liability method to record income tax activity. Deferred taxes are determined based upon the estimated future tax effects of differences between the financial reporting and tax reporting bases of assets and liabilities, given the provisions of currently enacted tax laws. The accounting for uncertainty in income taxes recognized in an enterprise’s financial statements uses the threshold of more-likely-than-not to be sustained upon examination for inclusion or exclusion. Measurement of the tax uncertainty occurs if the recognition threshold has been met. Net Earnings (Losses) Per Common Share The Company accounts for net loss per share in accordance with Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”), which requires presentation of basic and diluted earnings per share (“EPS”) on the face of the statement of operations for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS. Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during each period. It excludes the dilutive effects of any potentially issuable common shares. The effect of common stock equivalents is anti-dilutive with respect to losses and therefore basic and dilutive is the same. Diluted net loss per share is calculated by including any potentially dilutive share issuances in the denominator. The following securities are excluded from the calculation of weighted average diluted shares at June 30, 2024 and December 31, 2023, respectively, because their inclusion would have been anti-dilutive. June 30, December 31, 2024 2023 Convertible notes outstanding 124,343 293,973 Convertible preferred stock outstanding 39,090,908 39,090,908 Shares underlying warrants outstanding 7,500,000 87,500,000 46,715,251 126,884,881 Fair Value of Financial Instruments The fair value of financial instruments, which include cash, accounts payable and accrued expenses and advances from related parties were estimated to approximate their carrying values due to the immediate or short-term maturity of these financial instruments. Management is of the opinion that the Company is not exposed to significant interest, currency or credit risks arising from financial instruments. Fair value is defined as the price which would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-tier fair value hierarchy which prioritizes the inputs used in the valuation methodologies is as follows: Level 1 Inputs - Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 2 Inputs - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means. Level 3 Inputs - Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity’s own assumptions about the assumptions that market participants would use in pricing the assets or liabilities. At June 30, 2024 and December 31, 2023, the carrying amounts of the Company’s financial instruments, including cash, account payables, and accrued expenses, approximate their respective fair value due to the short-term nature of these instruments. At June 30, 2024 and December 31, 2023, the Company does not have any assets or liabilities except for derivative liabilities related to convertible notes payable required to be measured at fair value in accordance with FASB ASC Topic 820, Fair Value Measurement. The following presents the Company’s fair value hierarchy for those assets and liabilities measured at fair value as of June 30, 2024 and December 31, 2023: Level 1 Level 2 Level 3 Total June 30, 2024 Derivative liability - - 4,352 4,352 Total $ - $ - $ 4,352 $ 4,352 December 31, 2023 Derivative liability - - 2,146 2,146 Total $ - $ - $ 2,146 $ 2,146 Comprehensive Income The Company records comprehensive income as the change in equity of a business during a period from transactions and other events and circumstances from non-owner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners. Other comprehensive income (loss) includes foreign currency translation adjustments and unrealized gains and losses on available-for-sale securities. As of June 30 , 2024 and December 31, 2023, the Company had no items that represent comprehensive loss and, therefore, has not included a schedule of comprehensive loss in the financial statements. Stock Based Compensation Share-based compensation issued to employees is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period. The Company measures the fair value of the share-based compensation issued to non-employees at the grant date using the stock price observed in the trading market (for stock transactions) or the fair value of the award (for non-stock transactions), which were considered to be more reliably determinable measures of fair value than the value of the services being rendered. New Accounting Pronouncements In March 2020, No. 2020 04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting 2020 04 January 2021, 2021 01, Reference Rate Reform Scope December 2022, 2022 06, Reference Rate Reform Deferral of the Sunset Date of Topic 848 2020 04 December 31, 2024. not In June 2016, No. 2016 13, Financial Instruments Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments 2016 13 November 19, 2019, 2016 13 December 15, 2023, Other accounting standards and amendments to existing accounting standards that have been issued and have future effective dates are not applicable or are not expected to have a significant impact on the Company’s consolidated financial statements Going Concern The financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses since inception, resulting in an accumulated deficit of $66,027,771 and a working capital deficit of $25,730,147 as of June 30, 2024 and future losses are anticipated. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue its operations as a going concern is dependent on management’s plans, which include the raising of capital through debt and/or equity markets with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The Company will require additional funding to finance the growth of its current and expected future operations as well to achieve its strategic objectives. There can be no assurance that financing will be available in amounts or terms acceptable to the Company, if at all. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation and Basis of Presentation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Global Stem Cells Group Inc. (since August 18, 2021) and Cellular Hope Institute, wholly-owned subsidiary of Global Stem Cells Group Inc. All significant intercompany transactions have been eliminated in consolidation. Use of Estimates in Financial Statement Presentation The preparation of these financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The significant estimates included in these financial statements are associated with accounting for the goodwill, derivative liability, valuation of preferred stock, and for the valuation of assets and liabilities in business combination. Reclassifications Certain amounts for the prior year have been revised or reclassified to conform to the current year presentation. No change in net loss resulted from these reclassifications. Cash and Cash Equivalents The Company considers all highly liquid accounts with original maturities of three months or less to be cash equivalents. At December 31, 2023 and December 31, 2022, all of the Company’s cash was deposited in major banking institutions. There were no cash equivalents as of December 31, 2023 and December 31, 2022. Our cash balances at financial institutions may exceed the Federal Deposit Insurance Company’s (FDIC) insured limit of $250,000 from time to time. Accounts Receivable Accounts receivable are recorded at original invoice amount less an allowance for uncollectible accounts that management believes will be adequate to absorb estimated losses on existing balances. Management estimates the allowance based on collectability of accounts receivable and prior bad debt experience. Accounts receivable balances are written off against the allowance upon management’s determination that such accounts are uncollectible. Recoveries of accounts receivable previously written off are recorded when received. Management believes that credit risks on accounts receivable will not be material to the financial position of the Company or results of operations. The allowance for doubtful accounts was $0 and $0 as of December 31, 2023 and December 31, 2022, respectively. Intangible Assets Intangible assets with finite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are not amortized, but are tested for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. No impairment was recognized for the year ended December 31, 2023 and the year ended December 31, 2022. Goodwill We test our reporting unit for impairment annually at year end or more frequently if events or circumstances indicate it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the carrying amount of a reporting unit exceeds its estimated fair value, we record an impairment loss based on the difference between fair value and carrying amount of the reporting unit, not to exceed to the associated carrying amount of goodwill. (see Note 12 for detail of goodwill). Derivative Instruments The derivative instruments are accounted for as liabilities, the derivative instrument is initially recorded at its fair market value and is then re-valued at each reporting date, with changes in fair value recognized in operations for each reporting period. The Company uses the Monte Carlo option pricing model to value the derivative instruments. Revenue Recognition The Company recognizes revenue from the sale of products under ASC 606 by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. The Company recognizes revenue when it satisfies a performance obligation by transferring control over a product to a customer or services are provided. Revenue is measured based on the consideration the Company receives in exchange for those products. Income Taxes The Company uses the liability method to record income tax activity. Deferred taxes are determined based upon the estimated future tax effects of differences between the financial reporting and tax reporting bases of assets and liabilities, given the provisions of currently enacted tax laws. The accounting for uncertainty in income taxes recognized in an enterprise’s financial statements uses the threshold of more-likely-than-not to be sustained upon examination for inclusion or exclusion. Measurement of the tax uncertainty occurs if the recognition threshold has been met. Net Earnings (Losses) Per Common Share The Company accounts for net loss per share in accordance with Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”), which requires presentation of basic and diluted earnings per share (“EPS”) on the face of the statement of operations for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS. Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during each period. It excludes the dilutive effects of any potentially issuable common shares. The effect of common stock equivalents is anti-dilutive with respect to losses and therefore basic and dilutive is the same. Diluted net loss per share is calculated by including any potentially dilutive share issuances in the denominator. The following securities are excluded from the calculation of weighted average diluted shares at December 31, 2023 and 2022, respectively, because their inclusion would have been anti-dilutive. For the Years Ended 2023 2022 Convertible notes outstanding 293,973 365,463 Convertible preferred stock outstanding 39,090,908 39,447,283 Shares underlying warrants outstanding 87,500,000 103,500,000 126,884,881 143,312,746 Fair Value of Financial Instruments The fair value of financial instruments, which include cash, accounts payable and accrued expenses and advances from related parties were estimated to approximate their carrying values due to the immediate or short-term maturity of these financial instruments. Management is of the opinion that the Company is not exposed to significant interest, currency or credit risks arising from financial instruments. Fair value is defined as the price which would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-tier fair value hierarchy which prioritizes the inputs used in the valuation methodologies is as follows: Level 1 Inputs - Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 2 Inputs - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means. Level 3 Inputs - Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity’s own assumptions about the assumptions that market participants would use in pricing the assets or liabilities. At December 31, 2023 and December 31, 2022, the carrying amounts of the Company’s financial instruments, including cash, account payables, and accrued expenses, approximate their respective fair value due to the short-term nature of these instruments. At December 31, 2023 and December 31, 2022, the Company does not have any assets or liabilities except for derivative liabilities related to convertible notes payable required to be measured at fair value in accordance with FASB ASC Topic 820, Fair Value Measurement. The following presents the Company’s fair value hierarchy for those assets and liabilities measured at fair value as of December 31, 2023 and December 31, 2022: Level 1 Level 2 Level 3 Total December 31, 2023 Derivative liability 2,146 2,146 Total $ - $ - $ 2,146 $ 2,146 December 31, 2022 Derivative liability 6,944 6,944 Total $ - $ - $ 6,944 $ 6,944 Comprehensive Income The Company records comprehensive income as the change in equity of a business during a period from transactions and other events and circumstances from non-owner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners. Other comprehensive income (loss) includes foreign currency translation adjustments and unrealized gains and losses on available-for-sale securities. As of , 2023 and December 31, 2022, the Company had no items that represent comprehensive loss and, therefore, has not included a schedule of comprehensive loss in the financial statements. Stock Based Compensation Share-based compensation issued to employees is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period. The Company measures the fair value of the share-based compensation issued to non-employees at the grant date using the stock price observed in the trading market (for stock transactions) or the fair value of the award (for non-stock transactions), which were considered to be more reliably determinable measures of fair value than the value of the services being rendered. New Accounting Pronouncements In March 2020, No. 2020 04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting 2020 04 January 2021, 2021 01, Reference Rate Reform Scope December 2022, 2022 06, Reference Rate Reform Deferral of the Sunset Date of Topic 848 2020 04 December 31, 2024. not In June 2016, No. 2016 13, Financial Instruments Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments 2016 13 November 19, 2019, 2016 13 December 15, 2023, Other accounting standards and amendments to existing accounting standards that have been issued and have future effective dates are not applicable or are not expected to have a significant impact on the Company’s consolidated financial statements Going Concern The financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses since inception, resulting in an accumulated deficit of $61,990,131 and a working capital deficit of $21,674,139 as of December 31, 2023 and future losses are anticipated. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue its operations as a going concern is dependent on management’s plans, which include the raising of capital through debt and/or equity markets with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The Company will require additional funding to finance the growth of its current and expected future operations as well to achieve its strategic objectives. There can be no assurance that financing will be available in amounts or terms acceptable to the Company, if at all. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

Revenue Recognition

Revenue Recognition	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Revenue Recognition [Abstract]
REVENUE RECOGNITION	NOTE 3 – REVENUE RECOGNITION In accordance with FASB ASC 606, Revenue from Contracts with Customers (1) Identify the contract with a customer (2) Identify the performance obligations in the contract (3) Determine the transaction price (4) Allocate the transaction price to each performance obligation in the contract (5) Recognize revenue when each performance obligation is satisfied There was no material impact on the Company’s financial statements as a result of adopting Topic 606 for the six months ended June 30, 2024 and year ended December 31, 2023. The Company’s main source of revenue is comprised of the following: ● Training Completion of the seminar is when control is transferred and when revenue is recognized. ● Products Transfer of control is when the product is shipped, which is when revenue is recognized. ● Equipment Transfer of control is when the equipment is shipped, which is when revenue is recognized. ● Patient procedures are the treatments GSCG is offering at its Cancun clinic. The transfer of control is when the procedures are completed, which is when revenue is recognized. The Company recognizes revenue when it satisfies a performance obligation by transferring control over a product to a customer or as services are rendered. Revenue is measured based on the consideration the Company receives in exchange for those products. The following table presents the Company’s revenue by product category for the six months ended June 30, 2024 and 2023: For the Six Months Ended 2024 2023 Training $ 267,827 $ 291,464 Product supplies 769,237 629,456 Equipment 102,060 109,740 Patient procedures 471,259 116,897 Total revenue $ 1,610,363 $ 1,147,557 Listed below are the revenues, cost of revenues, gross profits, assets and net profit (loss) by Company: For the Six Months Ended June 30, 2024 Global Stem Meso Cells Group Numismatics Total Revenue $ 1,610,363 $ - $ 1,639,863 Cost of revenue 514,488 - 514,488 Gross profit $ 1,095,875 $ - $ 1,125,375 Gross Profit % 68.05 % 0.00 % 68.63 % Assets $ 1,168,726 $ 1,910,860 $ 3,079,586 Net profit (loss) $ (104,647 ) $ (3,932,993 ) $ (4,037,640 ) COVID-19 In December 2019, a novel strain of coronavirus was reported to have surfaced in Wuhan, China, which has and is continuing to spread throughout China and other parts of the world, including the United States. On January 30, 2020, the World Health Organization declared the outbreak of the coronavirus disease (COVID-19) a “Public Health Emergency of International Concern.” On January 31, 2020, U.S. Health and Human Services Secretary Alex M. Azar II declared a public health emergency for the United States to aid the U.S. healthcare community in responding to COVID-19, and on March 11, 2020 the World Health Organization characterized the outbreak as a “pandemic”. The significant outbreak of COVID-19 resulted in a widespread health crisis that adversely affected the economies and financial markets in which we operate. Restrictions in international travel along with in person meetings limited our training of new customers along with selling them products and equipment which adversely affecting our results of operations and financial condition during 2021 and the first six months of 2022. During the fourth quarter of 2022 and into 2023 we started recovering from the COVID-19 pandemic with restrictions in international travel removed along with the opening of the Cancun facility in the second half of 2022, which provided a facility for physicians to come for training and preform patient procedures. The full extent of the future impacts of COVID-19 on the Company’s operations is uncertain. A prolonged outbreak could have a material adverse impact on financial results and business operations of the Company, including the timing and ability of the Company to collect accounts receivable and the ability of the Company to continue to provide high-quality services and equipment. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities at the date of issuance of these financial statements. These estimates may change as new events occur and additional information is obtained.	NOTE 3 – REVENUE RECOGNITION In accordance with FASB ASC 606, Revenue from Contracts with Customers (1) Identify the contract with a customer (2) Identify the performance obligations in the contract (3) Determine the transaction price (4) Allocate the transaction price to each performance obligation in the contract (5) Recognize revenue when each performance obligation is satisfied There was no material impact on the Company’s financial statements as a result of adopting Topic 606 for the years ended December 31, 2023 and December 31, 2022. The Company’s main source of revenue is comprised of the following: ● Training Completion of the seminar is when control is transferred and when revenue is recognized. ● Products Transfer of control is when the product is shipped, which is when revenue is recognized. ● Equipment Transfer of control is when the equipment is shipped which is when revenue is recognized. ● Patient procedures are the treatments GSCG is offering at its Cancun clinic. The transfer of control is when the procedures are completed, which is when revenue is recognized. The Company recognizes revenue when it satisfies a performance obligation by transferring control over a product to a customer or as services are rendered. Revenue is measured based on the consideration the Company receives in exchange for those products. The following table presents the Company’s revenue by product category for the years ended December 31, 2023 and 2022: For the Years Ended 2023 2022 Training $ 599,425 $ 279,404 Product supplies 1,329,159 866,104 Equipment 162,370 163,460 Patient procedures 318,999 221,255 Total revenue $ 2,409,953 $ 1,530,223 Listed below are the revenues, cost of revenues, gross profits, assets and net loss by Company: For the Year Ended December 31, 2023 Global Stem Meso Cells Group Numismatics Total Revenue $ 2,409,953 $ - $ 2,409,953 Cost of revenue 734,285 - 734,285 Gross profit $ 1,675,668 $ - $ 1,675,668 Gross Profit % 69.53 % 0.00 % 69.53 % Assets $ 908,171 $ 1,970,932 $ 2,879,103 Net loss $ (323,109 ) $ (9,490,557 ) $ (9,813,666 ) COVID-19 In December 2019, a novel strain of coronavirus was reported to have surfaced in Wuhan, China, which has and is continuing to spread throughout China and other parts of the world, including the United States. On January 30, 2020, the World Health Organization declared the outbreak of the coronavirus disease (COVID-19) a “Public Health Emergency of International Concern.” On January 31, 2020, U.S. Health and Human Services Secretary Alex M. Azar II declared a public health emergency for the United States to aid the U.S. healthcare community in responding to COVID-19, and on March 11, 2020 the World Health Organization characterized the outbreak as a “pandemic”. The significant outbreak of COVID-19 resulted in a widespread health crisis that adversely affected the economies and financial markets in which we operate. Restrictions in international travel along with in person meetings limited our training of new customers along with selling them products and equipment which adversely affecting our results of operations and financial condition during 2021 and the first six months of 2022. During the fourth quarter of 2022 and into 2023 we started recovering from the COVID-19 pandemic with restrictions in international travel removed along with the opening of the Cancun facility in the second half of 2022, which provided a facility for physicians to come for training and preform patient procedures. The full extent of the future impacts of COVID-19 on the Company’s operations is uncertain. A prolonged outbreak could have a material adverse impact on financial results and business operations of the Company, including the timing and ability of the Company to collect accounts receivable and the ability of the Company to continue to provide high-quality services and equipment. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities at the date of issuance of these financial statements. These estimates may change as new events occur and additional information is obtained.

Notes Payable

Notes Payable	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Notes Payable [Abstract]
NOTES PAYABLE	NOTE 4 – NOTES PAYABLE Convertible Notes Payable On November 25, 2019, the Company, pursuant to the certificate of designation of the Series BB Preferred Stock, elected to exchange the preferred shares for other indebtedness calculated at a price per share equal to $1.20. Upon the Company’s mailing of the Exchange Agreement, the shareholder had the option, within 30 days of such mailing date and subject to the execution of this Agreement to receive the Indebtedness in the form of a convertible note. If the shareholder did not give the Company notice, the indebtedness shall automatically be issued in the form of a promissory note. The convertible note agreements bear no interest and have a four (4) year maturity date. The notes may be repaid in whole or in part at any time prior to maturity. There are no shares of common stock issuable upon the execution of the promissory notes. The notes are convertible, at the investors’ sole discretion, into shares of common stock at conversion price equal to the lowest bid price of the Common Stock as reported on the National Quotations Bureau OTC Markets exchange for the three prior trading days including the day upon which a Notice of Conversion is received by the Company. As of December 31, 2019, 81,043 Preferred Series BB shares were exchanged for an aggregate of $97,252 convertible notes. During the periods ending June 30, 2024 and December 31, 2023, the Company made payments of $0 and $9,850, respectively, on the outstanding convertible notes. The balance of the convertible notes as of June 30, 2024 and December 31, 2023 is as follows: June 30, December 31, 2024 2023 Convertible notes payable $ 44,939 $ 57,252 Less: Discount (4,958 ) (9,916 ) Convertible notes payable, net $ 39,981 $ 35,023 During the periods ending June 30, 2024 and December 31, 2023, the Company incurred $4,958 and $7,679, respectively, of debt discount amortization expense and made payments of $0 and $9,850, respectively, on the outstanding convertible notes. As of June 30, 2024 and December 31, 2023, the Company had no Promissory Notes Payable During 2015, the Company entered into line of credit with Digital Arts Media Network that was treated as a promissory note. The promissory note bears interest at ten (10%) per annum and has a one (1) year maturity date. The note may be repaid in whole or in part at any time prior to maturity. There are no shares of common stock issuable upon the execution of the promissory note. As of June 30, 2024 and December 31, 2023, the principal balance of the outstanding note was $130,025 and $130,025, respectively, and accrued interest of $112,050 and $105,602, respectively. On November 25, 2019, pursuant to the certificate of designation of the Series BB Preferred Stock, the Company elected to exchange the preferred shares for other indebtedness calculated at a price per share equal to $1.20. Upon the Company’s mailing of the Exchange Agreement, each shareholder had the option, within 30 days of such mailing date, to receive the indebtedness in the form of a convertible note. If the shareholder does not give the Company notice, the indebtedness shall automatically be issued in the form of a promissory note without any conversion feature. The promissory notes bear no interest and have a four (4) year maturity date with a 20% premium to be paid upon maturity. The notes may be repaid in whole or in part at any time prior to maturity. As of December 31, 2019, 276,723 Preferred Series BB shares were exchanged for an aggregate of $332,068 promissory notes. As of June 30, 2024 and December 31, 2023, the aggregate loan balances outstanding were $398,482 and $398,482, respectively, and unamortized discount of $4,017 and $8,033, respectively. On December 3, 2019, Melvin Pereira, the prior CEO, converted 18,500 shares of the 25,000 shares of Series BB preferred stock to acquire one hundred (100%) percent of Meso’s common stock into 250,999 shares of the Company’s common stock and elected to exchange the remaining 6,500 shares of Series BB preferred stock for a promissory note of $7,800, which is shown as a related party note payable on the balance sheet on June 30, 2024 and December 31, 2023. At December 7, 2020, the Company exchanged $5,379,624 of principal, default penalty and accrued but unpaid interest on convertible notes for $5,379,624 promissory notes and cashless warrants to purchase 15,000,000 shares of our common stock with three separate lenders. The new notes have a maturity date of November 23, 2023 and an aggregate principal amount of $5,379,624 that bear interest at a fifteen (15%) percentage compounded annual interest rate and, as an incentive, we have issued cashless warrants to purchase 15,000,000 shares of our common stock at an exercise price of $0.03 per share in connection with the restructuring. The Company recorded the fair value of the 15,000,000 warrants issued with debt at approximately $262,376 at December 31, 2020 as a discount. The lenders were granted security interests and liens in all rights, title and interest in the assets and property of the Company as collateral. On November 20, 2023, both the Company and two separate lenders agreed to terminate the notes in the amount of $2,506,827 in exchange for an aggregate consideration of $300,000 and new notes. As of June 30, 2024 and December 31, 2023, the aggregate loan balances outstanding were $2,872,797 and $2,872,797, respectively, and unamortized discount of $0 and $0, respectively. This loan is currently in default. The new notes have a maturity date of November 20, 2028, an aggregate principal amount of $1,999,999, and bear interest at a six (6%) percentage annual interest rate. In accordance with ASC 470-50-40-10 and ASC 470-50-40-11 guidance the Company has determined that this should be treated as a debt extinguishment. Since the old debt was derecognized and new debt was recorded at fair value a gain was recorded between the net carrying value of the original debt and the fair value of the new debt. The consideration was paid to the existing lender and not a third party therefore the consideration was expensed as an offset to the gain. As of June 30, 2024 and December 31, 2023, the outstanding loan balance was $1,999,999 and $1,999,999, respectively. On December 9, 2020, the Company entered into a Promissory Debenture with a lender in the amount of $110,000, which bears compounded annual interest at fifteen (15%) percent and has a two (2) year maturity date and cashless warrants to purchase 1,000,000 shares of our common stock at exercise prices of $0.03 per share. The note may be repaid in whole or in part at any time prior to maturity. The lender had advanced a total of $100,000, net of discount in the amount of $10,000 to the Company. The Company recorded the fair value of the 1,000,000 warrants issued with debt at approximately $17,491 at December 31, 2020 as a discount. As of June 30, 2024 and December 31, 2023, the outstanding loan balance was $110,000 and $110,000, respectively, and unamortized discount of $0 and $0, respectively. This loan is currently in default. On January 6, 2021, the Company entered into a Promissory Debenture with a lender in the amount of $1,000,000, which bears interest at fifteen (15%) percent and has a one (1) year maturity date and cashless warrants to purchase 10,000,000 shares of our common stock, at exercise prices of $0.03 per share. The note may be repaid in whole or in part at any time prior to maturity. The lender had advanced a total of $900,000, net of discount in the amount of $100,000 to the Company. The Company recorded the fair value of the 10,000,000 warrants issued with debt at approximately $237,811 at the date of issuance as a discount. As of June 30, 2024 and December 31, 2023, the outstanding loan balance was $1,000,000 and $1,000,000, respectively, and unamortized discount of $0.00 and $0.00, respectively. This loan is currently in default. On June 22, 2021, the Company entered into a Promissory Debenture with a lender in the amount of $11,600,000, which bears interest at twelve (12%) percent and has a three (3) year maturity date and cashless warrants to purchase 70,000,000 shares of our common stock, at exercise prices of $0.10 per share. The notes may be repaid in whole or in part at any time prior to maturity. The lender had advanced a total of $10,500,000, net of discount in the amount of $1,100,000 to the Company. The Company recorded the fair value of the 70,000,000 warrants issued with debt at approximately $5,465,726 at the date the warrants were issued as a discount. The lender has been granted a senior security interest and lien in all rights, title and interest in the assets and property of the Company as collateral. As of June 30, 2024 and December 31, 2023, the outstanding loan balance was $11,600,000 and $11,600,000, respectively, and unamortized discount of $0.00 and $1,927,351, respectively. This loan is currently in default. On August 18, 2021, through a Stock Purchase Agreement in which the Company acquired 100% of the outstanding shares of Global Stem Cell Group, Inc., the Company acquired a 2018 Jaguar F-Pace which was acquired from Benito Novas for $45,000 on January 8, 2019 and assumed the related auto loan, with an original loan amount of $20,991 at 8.99% interest for 48 months and monthly payments of $504.94. As of June 30, 2024 and December 31, 2023, the principal balance of the outstanding auto loan was $0.00 and $0.00, respectively. On August 18, 2021, through a Stock Purchase Agreement in which the Company acquired 100% of the outstanding shares of Global Stem Cell Group, Inc., the Company assumed the November 17, 2020, agreement with an investor for proceeds in the amount of $400,000 treated as a promissory. In exchange for the gross proceeds, the investor shall receive the right to a perpetual 7.75% (payment percentage) of the revenues of Global Stem Cell Group. The payments of the payment percentage shall be calculated by multiplying the gross quarterly revenues appearing in the financial statements by the payment percentage and treated as accrued interest. Payments shall be made ninety (90) days from the end of each respective fiscal quarter with the first payment to be made on the quarter ending December 31, 2020. Payments may be accrued and deferred if payment would deplete cash, cash equivalent and/or short-term investment balances on each respective fiscal quarter by more than twenty (20%) percent. As of June 30, 2024 and December 31, 2023, the principal balance of the outstanding loan was $400,000 and $400,000, respectively, and accrued interest totals $519,640 and $392,551, respectively. This debt instrument is currently in default due to the non-payment of interest. On September 20, 2021, the Company entered into a Promissory Debenture with a lender in the amount of $1,100,000, which bears interest at twelve (12%) percent and has a three (3) year maturity date and cashless warrants to purchase 7,500,000 shares of our common stock, at exercise prices of $0.085 per share. The note may be repaid in whole or in part at any time prior to maturity. The lender had advanced a total of $1,000,000, net of discount in the amount of $100,000 to the Company. The Company recorded the fair value of the 7,500,000 warrants issued with debt at approximately $360,607 at the time of issuance as a discount. As of June 30, 2024 and December 31, 2023, the outstanding loan balance was $1,100,000 and $1,100,000, respectively, and unamortized discount of $61,489 and $181,381, respectively. On December 30, 2021, the parties modified the terms of the Promissory Debenture dated July 13, 2020 in the amount of $6,000 and accrued interest in the amount of $1,578 by issuing a new promissory note and extending the date of maturity. In consideration for the new terms, the Promissory Debenture dated December 30, 2021 shall include a five (5%) percent premium for a total of $7,958 which bears interest at twelve (12%) percent and has a seventeen (17) months maturity date. The note may be repaid in whole or in part at any time prior to maturity. As of June 30, 2024 and December 31, 2023, the outstanding loan balance was $7,958 and $7,958, respectively, and unamortized discount of $0.00 and $0.00, respectively. This loan is currently in default. On December 30, 2021, the parties modified the terms of the Promissory Debenture dated July 15, 2020 in the amount of $84,000 and accrued interest in the amount of $22,162 by issuing a new promissory note and extending the date of maturity. In consideration for the new terms, the Promissory Debenture dated December 30, 2021 shall include a five (5%) percent premium for a total of $111,470 which bear interest at twelve (12%) percent and have a seventeen (17) months maturity date. The notes may be repaid in whole or in part at any time prior to maturity. As of June 30, 2024 and December 31, 2023, the outstanding loan balance was $111,470 and $111,470, respectively, and unamortized discount of $0.00 and $0.00, respectively. This loan is currently in default. The balance of the promissory notes as of June 30, 2024 and December 31, 2023 is as follows: June 30, December 31, 2024 2023 Promissory notes payable $ 19,722,931 $ 19,722,931 Promissory notes payable-related party 7,800 7,800 Less: Discount (65,506 ) (2,100,966 ) Less: Deferred finance costs - (15,798 ) Promissory notes payable, net $ 19,665,225 $ 17,613,966 During the periods ending June 30, 2024 and December 31, 2023, the Company made $0 and $300,000 payments, respectively, on the outstanding promissory notes, and recorded $1,533,042 and $3,244,361, respectively, of interest expense and $2,051,259 and $3,049,999, respectively, of debt discount amortization expense and recorded $1,511,297 gain on extinguishment of debt. As of June 30, 2024 and December 31, 2023, the Company had approximately $8,130,463 and $6,597,422, respectively, of accrued interest. As of June 30, 2024 and December 31, 2023, the principal balance of outstanding promissory notes payable was $19,730,731 and $19,730,731, respectively. Derivatives Liabilities The Company determined that the convertible notes outstanding as of June 30, 2024 contained an embedded derivative instrument as the conversion price was based on a variable that was not an input to the fair value of a “fixed-for-fixed” option as defined under FASB ASC Topic No. 815 – 40. The Company determined the fair values of the embedded convertible notes derivatives and tainted convertible notes using the lattice valuation model with the following assumptions: June 30, 2024 Common stock issuable 124,343 Market value of common stock on measurement date $ 0.035 Adjusted exercise price $ 0.06 Risk free interest rate 5.01 % Instrument lives in years 0.50 Year Expected volatility 99.80 % Expected dividend yields None At December 7, 2020, the Company exchanged $5,379,624 of principal, default penalty and accrued but unpaid interest on convertible notes for $5,379,624 promissory notes and cashless warrants to purchase 15,000,000 shares of our common stock which eliminated the derivative liability associated with this debt. The balance of the fair value of the derivative liability as of June 30, 2024 and December 31, 2023 is as follows: Balance at December 31, 2022 $ 6,944 Additions - Fair value loss (3,450 ) Conversions (1,348 ) Balance at December 31, 2023 2,146 Additions - Fair value loss 2,206 Conversions - Balance at June 30, 2024 $ 4,352	NOTE 4 – NOTES PAYABLE Convertible Notes Payable On November 25, 2019, the Company, pursuant to the certificate of designation of the Series BB Preferred Stock, elected to exchange the preferred shares for other indebtedness calculated at a price per share equal to $1.20. Upon the Company’s mailing of the Exchange Agreement, the shareholder had the option, within 30 days of such mailing date to receive the indebtedness in the form of a convertible note. If the shareholder did not give the Company notice, the indebtedness shall automatically be issued in the form of a promissory note without any conversion feature. The convertible note agreements bear no interest and have a four (4) year maturity date. The convertible notes are convertible, at the investors’ sole discretion, into shares of common stock at conversion price equal to the lowest bid price of the Common Stock as reported on the National Quotations Bureau OTC Markets exchange for the three prior trading days including the day upon which a Notice of Conversion is received by the Company. There are no shares of common stock issuable upon the execution of the promissory notes. The convertible notes may be repaid in whole or in part at any time prior to maturity. As of December 31, 2019, 81,043 Preferred Series BB shares were exchanged for an aggregate of $97,252 convertible notes. During the periods ending December 31, 2023 and December 31, 2022, the Company made payments of $9,850 and $15,000, respectively, on the outstanding convertible notes. The balance of the convertible notes as of December 31, 2023 and December 31, 2022 is as follows: December 31, December 31, 2023 2022 Convertible notes payable $ 44,939 $ 57,252 Less: Discount 9,916 19,833 Convertible notes payable, net $ 35,023 $ 37,419 During the periods ending December 31, 2023 and December 31, 2022, the Company incurred $9,917 and $18,437, respectively, of debt discount amortization expense and made payments of $9,850 and $15,000, respectively, on the outstanding convertible notes. As of December 31, 2023 and December 31, 2022, the Company had no accrued interest on the above notes. Promissory Notes Payable During 2015, the Company entered into line of credit with Digital Arts Media Network treated as a promissory note. The promissory note bear interest at ten (10%) and have a one (1) year maturity date. The notes may be repaid in whole or in part at any time prior to maturity. There are no shares of common stock issuable upon the execution of the promissory notes. As of December 31, 2023 and December 31, 2022, the principal balance of the outstanding loan was $130,025 and $130,025, respectively, and accrued interest of $105,602 and $92,600, respectively. On November 25, 2019, the Company, pursuant to the certificate of designation of the Series BB Preferred Stock, elected to exchange the preferred shares for other indebtedness calculated at a price per share equal to $1.20. Upon the Company’s mailing of the Exchange Agreement, the shareholder had the option, within 30 days of such mailing date to receive the indebtedness in the form of a convertible note. If the shareholder did not give the Company notice, the indebtedness shall automatically be issued in the form of a promissory note without any conversion feature. The promissory notes bear no interest and have a four (4) year maturity date with a 20% premium to be paid upon maturity. The notes may be repaid in whole or in part at any time prior to maturity. As of December 31, 2019, 276,723 Preferred Series BB shares were exchanged for an aggregate of $332,068 promissory notes. As of December 31, 2023 and December 31, 2022, the aggregate loan balances outstanding was $398,482 and $398,482, respectively, and unamortized discount of $8,033 and $16,083, respectively. On December 3, 2019, Melvin Pereira, the prior CEO, converted 18,500 shares of the 25,000 shares of Series BB preferred stock to acquire one hundred (100%) percent of Meso’s common stock into 250,999 shares of the Company’s common stock and elected to exchange the remaining 6,500 shares of Series BB preferred stock for a promissory note of $7,800, which is shown as a related party note payable on the balance sheet on December 31, 2023 and December 31, 2022. At December 7, 2020 the Company exchanged $5,379,624 of principal, default penalty and accrued but unpaid interest on convertible notes for $5,379,624 promissory notes and cashless warrants to purchase 15,000,000 shares of our common stock with three separate lenders. The new notes have a maturity date of November 23, 2023 and an aggregate principal amount of $5,379,624 shall bear interest at a fifteen (15%) percentage compounded annual interest rate and, as an incentive; we have issued cashless warrants to purchase 15,000,000 shares of our common stock at an exercise price of $0.03 per share in connection with the restructuring. The Company recorded the fair value of the 15,000,000 warrants issued with debt at approximately $262,376 at December 31, 2020 as a discount. Lender is granted security interest and lien in all rights, title and interest in the assets and property of the as collateral. On November 20, 2023 both the Company and two separate lenders hereby agree to terminate the 2020 Secured Note in the amount of $2,506,827 in exchange for an aggregate consideration of $300,000 and new notes. The 2020 Secured Note shall become null and void and the Company shall no longer be liable for any amounts related to the 2020 Secured Note. As of December 31, 2023 and December 31, 2022, the aggregate loan balances outstanding was $2,872,797 and $5,379,624, respectively, and unamortized discount of $0 and $81,700, respectively. On December 9, 2020, the Company entered into a Promissory Debentures with a lender in the amount of $110,000 which bear compounded annual interest at fifteen (15%) percent and have a two (2) year maturity date and cashless warrants to purchase 1,000,000 shares of our common stock. The notes may be repaid in whole or in part at any time prior to maturity. The lender had advanced a total of $100,000, net of discount in the amount of $10,000 to the Company. The Company recorded the fair value of the 1,000,000 warrants issued with debt at approximately $17,491 at December 31, 2020 as a discount. As of December 31, 2023 and December 31, 2022, the outstanding loan balance was $110,000 and $110,000, respectively, and unamortized discount of $0 and $8,611, respectively. On January 6, 2021, the Company entered into a Promissory Debentures with a lender in the amount of $1,000,000 which bear interest at fifteen (15%) percent and have a one (1) year maturity date and cashless warrants to purchase 10,000,000 shares of our common stock, at exercise prices of $0.03 per share. The notes may be repaid in whole or in part at any time prior to maturity. The lender had advanced a total of $900,000, net of discount in the amount of $100,000 to the Company. The Company recorded the fair value of the 10,000,000 warrants issued with debt at approximately $237,811 at the date of issuance as a discount. As of December 31, 2023 and December 31, 2022, the outstanding loan balance was $1,000,000 and $1,000,000, respectively, and unamortized discount of $0.00 and $0.00, respectively. This loan is currently in default. On June 22, 2021, the Company entered into a Promissory Debentures with a lender in the amount of $11,600,000 which bear interest at twelve (12%) percent and have a three (3) year maturity date and cashless warrants to purchase 70,000,000 shares of our common stock, at exercise prices of $0.10 per share. The notes may be repaid in whole or in part at any time prior to maturity. The lender had advanced a total of $10,500,000, net of discount in the amount of $1,100,000 to the Company. The Company recorded the fair value of the 70,000,000 warrants issued with debt at approximately $5,465,726 at the date the warrants were issued as a discount. Lender is granted senior security interest and lien in all rights, title and interest in the assets and property of the Company as collateral. As of December 31, 2023 and December 31, 2022, the outstanding loan balance was $11,600,000 and $11,600,000, respectively, and unamortized discount of $1,927,351 and $4,707,853, respectively. On August 18, 2021, through a Stock Purchase Agreement in which 100% of the outstanding shares of Global Stem Cell Group, Inc. the Company acquired a 2018 Jaguar F-Pace which was acquired from Benito Novas for $45,000 on January 8, 2019 and assumed the related auto loan, with an original loan amount of $20,991 at 8.99% interest for 48 months and monthly payments of $504.94. As of December 31, 2023 and December 31, 2022, the principal balance of the outstanding auto loan was $0.00 and $0.00, respectively. On August 18, 2021, through a Stock Purchase Agreement in which 100% of the outstanding shares of Global Stem Cell Group, Inc. the Company assumed the November 17, 2020, agreement with an Investor for proceeds in the amount of $400,000 treated as a promissory. In exchange for the gross proceeds, the Investor shall receive the right to a perpetual 7.75% (payment percentage) of the revenues of Global Stem Cell Group. The payments of the payment percentage shall be calculated by multiplying the gross quarterly revenues appearing in the financial statements by the payment percentage and treated as accrued interest. Payments shall be made ninety (90) days from the end of each respective fiscal quarter with the first payment to be made on the quarter ending December 31, 2020. Payments may be accrued and deferred if payment would deplete cash, cash equivalent and/or short-term investment balances on each respective fiscal quarter by more than twenty (20%) percent. As of December 31, 2023 and December 31, 2022, the principal balance of the outstanding loan was $400,000 and $400,000, respectively, and accrued interest totals $392,551 and $205,779, respectively. This debt instrument is currently in default due to the non-payment of interest. On September 20, 2021, the Company entered into a Promissory Debentures with a lender in the amount of $1,100,000 which bear interest at twelve (12%) percent and have a three (3) year maturity date and cashless warrants to purchase 7,500,000 shares of our common stock, at exercise prices of $0.085 per share. The notes may be repaid in whole or in part at any time prior to maturity. The lender had advanced a total of $1,000,000, net of discount in the amount of $100,000 to the Company. The Company recorded the fair value of the 7,500,000 warrants issued with debt at approximately $360,607 at the time of issuance as a discount. As of December 31, 2023 and December 31, 2022, the outstanding loan balance was $1,100,000 and $1,100,000, respectively, and unamortized discount of $181,381 and $350,416, respectively. On December 30, 2021, the parties wished to modify the terms of the Promissory Debentures dated July 13, 2020 in the amount of $6,000 and accrued interest in the amount of $1,578 by issuing a new promissory note and extend the date of maturity. In consideration for the new terms, the Promissory Debenture dated December 30, 2021 shall include a five (5%) percent premium for a total of $7,958 which bear interest at twelve (12%) percent and have a seventeen (17) months maturity date. The notes may be repaid in whole or in part at any time prior to maturity. As of December 31, 2023 and December 31, 2022, the outstanding loan balance was $7,958 and $7,958, respectively, and unamortized discount of $0.00 and $139, respectively. On December 30, 2021, the parties wished to modify the terms of the Promissory Debentures dated July 15, 2020 in the amount of $84,000 and accrued interest in the amount of $22,162 by issuing a new promissory note and extend the date of maturity. In consideration for the new terms, the Promissory Debenture dated December 30, 2021 shall include a five (5%) percent premium for a total of $111,470 which bear interest at twelve (12%) percent and have a seventeen (17) months maturity date. The notes may be repaid in whole or in part at any time prior to maturity. As of December 31, 2023 and December 31, 2022, the outstanding loan balance was $111,470 and $111,470, respectively, and unamortized discount of $0.00 and $1,950, respectively. On November 20, 2023 both the Company and two separate lenders hereby agree to terminate the 2020 Secured Note in the amount of $2,506,827 in exchange for an aggregate consideration of $300,000 and new notes. The new notes have a maturity date of November 20, 2028 and an aggregate principal amount of $1,999,999 shall bear interest at a six (6%) percentage annual interest rate. In accordance with ASC 470-50-40-10 and ASC 470-50-40-11 guidance the Company has determined that this should be treated as a debt extinguishment. Since the old debt was derecognized and new debt was recorded at fair value a gain was recorded between the net carrying value of the original debt and the fair value of the new debt. The consideration was paid to the existing lender and not a third party therefore the consideration was expensed as an offset to the gain. The balance of the promissory as of December 31, 2023 and December 31, 2022 is as follows: December 31, December 31, 2023 2022 Promissory notes payable $ 19,730.731 $ 20,237,559 Less: Discount 2,100,966 5,117,631 Less: Deferred finance costs 15,798 49,132 Promissory notes payable, net $ 17,613,966 $ 15,070,796 During the periods ending December 31, 2023 and December 31, 2022, the Company made $300,000 and $5,776 payments, respectively on the outstanding promissory notes, and recorded $3,244,361 and $2,898,155, respectively, of interest expense and $3,049,999 and $1,738,327, respectively, of debt discount amortization expense and recorded $1,511,297 gain on extinguishment of debt. As of December 31, 2023 and December 31, 2022, the Company had approximately $6,597,422 and $4,657,529, respectively, of accrued interest. As of December 31, 2023 and December 31, 2022, the principal balance of outstanding promissory notes payable was $19,730,731 and $20,237,559, respectively. Derivatives Liabilities The Company determined that the convertible notes outstanding as of December 31, 2023 contained an embedded derivative instrument as the conversion price was based on a variable that was not an input to the fair value of a “fixed-for-fixed” option as defined under FASB ASC Topic No. 815 – 40. The Company determined the fair values of the embedded convertible notes derivatives and tainted convertible notes using the lattice valuation model with the following assumptions: December 31, 2023 Common stock issuable 293,973 Market value of common stock on measurement date $0.0073 Adjusted exercise price $0.06 Risk free interest rate 4.75% Instrument lives in years 1.00 Year Expected volatility 83% Expected dividend yields None At December 7, 2020 the Company exchanged $5,379,624 of principal, default penalty and accrued but unpaid interest on convertible notes for $5,379,624 promissory notes and cashless warrants to purchase 15,000,000 shares of our common stock which eliminated the derivative liability associated with this debt. The balance of the fair value of the derivative liability as of December 31, 2023 and December 31, 2022 is as follows: Balance at December 31, 2021 $ 20,442 Additions - Fair value loss (10,856 ) Conversions (2,642 Balance at December 31, 2022 6,944 Additions - Fair value gain (3,450 ) Conversions (1,348 ) Balance at December 31, 2023 $ 2,146

Stockholders Equity

Stockholders Equity	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Stockholders Equity [Abstract]
STOCKHOLDERS EQUITY	NOTE 5 – STOCKHOLDERS EQUITY Common Shares The Board of Directors and shareholders were required to increase the number of authorized shares of common stock from (a) 200,000,000 to 500,000,000 during June 2015, (b) 500,000,000 to 1,500,000,000 during July 2015, and (c) 1,500,000,000 to 6,500,000,000 during March 2016, to adhere to the Company’s contractual obligation to maintain the required reserve share amount for debtholders. 2024 Transactions The Company has not issued any of its authorized capital stock for the quarter ended June 30, 2024. 2023 Transactions On December 8, 2023, the Company issued 50,000 shares of common stock for commitment shares as part of an Equity Financing Agreement, which were valued in the amount of $455. As of June 30, 2024 and December 31, 2023, the Company has 12,493,938 and 12,493,938 common shares issued and outstanding, respectively. Warrants During the year ended December 31, 2020, the Company issued warrants to purchase 16,000,000 shares of common stock, at an exercise price of $0.03 per share. These warrants expire three years from issuance date. The Company recorded the fair value of the 16,000,000 warrants issued with debt at approximately $279,867 at December 31, 2020 as a discount. On January 6, 2021, the Company issued warrants to purchase 10,000,000 shares of common stock, at an exercise price of $0.033 per share. These warrants expire three years from issuance date. The Company recorded the fair value of the 10,000,000 warrants issued with debt at approximately $237,811 as a discount. On June 22, 2021, the Company issued warrants to purchase 70,000,000 shares of common stock, at an exercise price of $0.100 per share. These warrants expire three years from issuance date. The Company recorded the fair value of the 70,000,000 warrants issued with debt at approximately $5,465,726 as a discount. On September 20, 2021, the Company issued warrants to purchase 7,500,000 shares of common stock, at an exercise price of $0.085 per share. These warrants expire three years from issuance date. The Company recorded the fair value of the 7,500,000 warrants issued with debt at approximately $360,607 as a discount. The following table summarizes the Company’s warrant transactions during the six months ended June 30, 2024 and the year ended December 31, 2023: Number of Weighted Outstanding at year ended December 31, 2022 103,500,000 $ 0.082 Granted - - Exercised - - Expired (16,000,000 ) -0.03 Outstanding at year ended December 31, 2023 87,500,000 $ 0.091 Granted - - Exercised - - Expired (80,000,000 ) -0.092 Outstanding at quarter ended June 30, 2024 7,500,000 $ 0.091 Warrants granted in the year ended December 31, 2020 were valued using the Black Scholes Merton Model with the risk-free interest rate of 0.20%, expected life 3 years, expected dividend rate of 0% and expected volatility ranging of 411.72%. Warrants granted in the year ended December 31, 2021 were valued using the Black Scholes Merton Model with the risk-free interest rate within ranges between 0.20% to 0.45%, term of 3 years, dividend rate of 0% and historical volatility ranging between, 338.36% to 394.78%. The final value assigned to the warrants was determined using a relative fair value calculation between the amount of warrants and promissory notes. Designation of Series AA Super Voting Preferred Stock On June 30, 2014, the Company filed with the Secretary of State with Nevada an amendment to the Company’s Articles of Incorporation, authorizing the issuance of up to eleven million (11,000,000) shares of preferred stock, par value $0.001 per share. On May 2, 2014, the Company filed with the Secretary of State with Nevada in the form of a Certificate of Designation that authorized the issuance of up to one million (1,000,000) shares of a new series of preferred stock, par value $0.001 per share, designated “Series AA Super Voting Preferred Stock,” for which the board of directors established the rights, preferences and limitations thereof. All of the Holders of the Series AA Super Voting Preferred Stock together, voting separately as a class, shall have an aggregate vote equal to sixty-seven (67%) percent of the total vote on all matters submitted to the stockholders that each stockholder of the Corporation’s Common Stock is entitled to vote at each meeting of stockholders of the Corporation (and written actions of stockholders in lieu of meetings) with respect to any and all matters presented to the stockholders of the Corporation for their action and consideration. The holders of the Series AA Super Voting Preferred Stock shall not be entitled to receive dividends paid on the Company’s common stock. Upon liquidation, dissolution and winding up of the affairs of the Company, whether voluntary or involuntary, the holders of the Series AA Super Voting Preferred Stock shall not be entitled to receive out of the assets of the Company, whether from capital or earnings available for distribution, any amounts which will be otherwise available to and distributed to the common shareholders. The shares of the Series AA Super Voting Preferred Stock will not be convertible into the shares of the Company’s common stock. On November 26, 2019, the Company filed with the Secretary of State with Nevada an amendment to the Company’s Articles of Incorporation, authorizing the increase to 1,050,000 shares of the Series AA Super Voting Preferred Stock. The amended certificate of designation for the Series AA Preferred Stock further provides that a unanimous consent of the holders of Series AA Preferred Stock is necessary for, among other things, a change in control of the Company, requiring the votes of both Messrs. Christensen and Novas. On June 26, 2020, Meso Numismatics, Inc. completed the repurchase of 1,000,000 shares of its Series AA Super Voting Preferred Stock for an aggregate total purchase price equal to $160,000, representing all of the Series AA Super Voting Preferred Stock held by E-Network de Costa Rica S.A. and S&M Chuah Enterprises Ltd., respectively. On June 26, 2020, due to Mr. Pereira’s resignation, the Company’s Board of Directors appointed Mr. David Christensen, current Director and President of the Company, to serve as Chief Executive Officer, Chief Financial Officer and Secretary, effective June 27, 2020 and granted 50,000 shares of Series AA Super Voting Preferred Stock to Mr. David Christensen. The $166,795 value of the 50,000 shares of Series AA Super Voting Preferred Stock to Mr. David Christensen is based on the 10,000 votes per preferred share to one vote per common share. Valuation based on definition of control premium is defined as the price to which a willing buyer and willing seller would agree in any arms-length transaction to acquire control of the Company. The premium paid above the market value of the company is real economic benefit to controlling the Company. Historically, the average control premium applied in M&A transactions averages approximately 30%, which represents the value of control. On August 18, 2021, the Company completed its acquisition of Global Stem Cells Group Inc., through a Stock Purchase Agreement acquiring all the outstanding capital stock of Global Stem Cells Group Inc and paid the purchase price of a total of 1,000,000 shares of Series AA Preferred Stock in the Company, 8,974 shares of Series DD Preferred Stock in the Company and $225,000 USD (the final payment of $50,000 was made on July 2, 2021). The Series AA Super Voting Preferred Stock issued on August 18, 2021, was valued based upon industry specific control premiums and the Company’s market cap at the time of the transaction. The $963,866 value of the 1,000,000 shares of Series AA Super Voting Preferred Stock issued to Benito Novas were valued based on a calculation by a third party independent valuation specialist. As of June 30, 2024 and December 31, 2023, the Company had 1,050,000 and 1,050,000 preferred shares of Series AA Preferred Stock issued and outstanding, respectively. During the period of these financial statements, no dividend was declared or paid on the Series AA preferred shares. Designation of Series BB Preferred Stock On March 29, 2017, the Company filed with the Secretary of State with Nevada in the form of a Certificate of Designation that authorized the issuance of up to one million (1,000,000) shares of a new series of preferred stock, par value $0.001 per share, designated “Series BB Preferred Stock,” for which the board of directors established the rights, preferences and limitations thereof. Each holder of outstanding shares of Series BB Preferred Stock shall be entitled to convert on a 1 for 1 basis into shares of the Company’s common stock, any or all of their shares of Series BB Preferred Stock after a minimum of six (6) months have elapsed from the issuance of the preferred stock to the holder. The Series BB Preferred Stock has no voting rights until the Holder redeems the preferred stock into the Company’s common stock. The Series BB Preferred Stock shall not be adjusted by the Corporation. The holders of the Series BB Preferred Stock shall not be entitled to receive dividends paid on the Company’s common stock. The Series BB Preferred Stock has a liquidation value of $1.00. Upon liquidation, dissolution and winding up of the affairs of the Company, whether voluntary or involuntary, the holders of the Series BB Preferred Stock shall be entitled to share equally and ratably in proportion to the preferred stock owned by the holder to receive out of the assets of the Company, whether from capital or earnings available for distribution, any amounts which will be otherwise available to and distributed to the common shareholders. As of December 31, 2019, 81,043 Preferred Series BB shares were exchanged for an aggregate of $97,252 convertible notes and 276,723 Preferred Series BB shares were exchanged for an aggregate of $332,068 promissory notes of which 78,620 were returned and cancelled and 279,146 were still outstanding at December 31, 2020. During the three months ended March 31, 2021, the remaining 279,146 were returned and cancelled. As of June 30, 2024 and December 31, 2023, the Company had no preferred shares of Series BB Preferred Stock issued and outstanding. Designation of Series CC Preferred Stock At any time prior to November 25, 2022 (“Automatic Conversion Date”) the Company may redeem for cash out of funds legally available therefor, any or all of the outstanding Series CC Convertible Preferred Stock at a price equal to $1,000 per share. If not converted prior, on the Automatic Conversion Date, any and all remaining issued and outstanding shares of Series CC Convertible Preferred Stock shall automatically convert at the Conversion Price, which is a price per share determined by dividing the number of issued and outstanding shares of common stock of the Company on the date of conversion by 1,000 and multiply the results by 0.8. Each holder of outstanding shares of Series CC Convertible Preferred Stock shall be entitled to convert, prior to the Automatic Conversion Date, part or all of its shares of Series CC Convertible Preferred Stock into a number of fully paid and nonassessable shares of common stock at a price per share determined by dividing the number of issued and outstanding shares of stock of the Company on the date of conversion by 1,000 and multiplying the results by 0.8 conversion price. The holders of the Series CC Convertible Preferred Stock shall not be entitled to receive dividends paid on the Company’s common stock. The holders of the Series CC Convertible Preferred Stock shall not be entitled to vote on any matter submitted to the shareholders of the Company for their vote, waiver, release or other action. As of June 30, 2024 and December 31, 2023, the Company had no preferred shares of Series CC Preferred Stock issued and outstanding. Designation of Series DD Convertible Preferred Stock On November 26, 2019, the Company filed with the Secretary of State with Nevada an amendment to the Company’s Articles of Incorporation, authorizing ten thousand (10,000) shares of a new series of preferred stock, par value $0.001 per share, designated “Series DD Convertible Preferred Stock,” for which the board of directors established the rights, preferences and limitations thereof. Each holder of outstanding shares of Series DD Convertible Preferred Stock shall be entitled to its shares of Series DD Convertible Preferred Stock into a number of fully paid and nonassessable shares of common stock determined by multiplying the number of issued and outstanding shares of common stock of the Company on the date of conversion by 3.17 conversion price. The holders of the Series DD Convertible Preferred Stock shall not be entitled to receive dividends paid on the Company’s common stock. The holders of the Series DD Convertible Preferred Stock shall not be entitled to vote on any matter submitted to the shareholders of the Company for their vote, waiver, release or other action. On August 18, 2021, the Company completed its acquisition of Global Stem Cells Group Inc., through a Stock Purchase Agreement acquiring all the outstanding capital stock of Global Stem Cells Group Inc and paid the purchase price of a total of 1,000,000 shares of Series AA Preferred Stock in the Company, 8,974 shares of Series DD Preferred Stock in the Company and $225,000 USD (the final payment of $50,000 was made on July 2, 2021). The $5,038,576 value of the 8,974 shares of Series DD Convertible Preferred Stock to Benito Novas is based on converting into a number of fully paid and nonassessable shares of common stock determined by multiplying the number of issued and outstanding shares of common stock of the Company on the date of conversion by 3.17 conversion price. The $5,038,576 value of the 8,974 shares of Series DD Convertible Preferred Stock represents the fair value of the consideration paid allocated to the assets and liabilities acquired from Global Stem Cells Group Inc. In consideration of mutual covenants set forth in the Professional Service Consulting Agreement, Dave Christensen, current Director, President, Chief Executive Officer, Chief Financial Officer and Secretary, shall be compensated monthly based on annual rate of $90,000, starting January 1, 2022. Additionally, the agreement includes an issuance of 896 shares of Series DD Preferred Stock of the Company. An amount of 448 shares were issued on August 18, 2021 and the remaining 448 were issued February 18, 2022. The $503,072 value of the 896 shares of Series DD Convertible Preferred Stock is based on converting into a number of fully paid and nonassessable shares of common stock determined by multiplying the number of issued and outstanding shares of common stock of the Company on the date of conversion by 3.17 conversion price. The $251,536 value of the 448 shares of Series DD Convertible Preferred Stock was recorded as stock payable at December 31, 2021 and issued on February 18, 2022. The full amount of $503,552 was expensed at the date of grant, as a matter of accounting policy. As of June 30, 2024 and December 31, 2023, the Company had 9,870 and 9,870 preferred shares of Series DD Convertible Preferred Stock issued and outstanding, respectively. During the period of these financial statements, no dividend was declared or paid on the Series DD preferred shares.	NOTE 5 – STOCKHOLDERS EQUITY Common Shares The Board of Directors and shareholders were required to increase the number of authorized shares of common stock from (a) 200,000,000 to 500,000,000 during June 2015, (b) 500,000,000 to 1,500,000,000 during July 2015, and (c) 1,500,000,000 to 6,500,000,000 during March 2016, to adhere to the Company’s contractual obligation to maintain the required reserve share amount for debtholders. 2022 Transactions On March 23, 2022, the Company issued 76,278 shares of common stock for consulting services, which were valued in the amount of $10,000. On May 5, 2022, the Company issued 89,485 shares of common stock for consulting services, which were valued in the amount of $10,000. On November 30, 2022, the Company issued 193,050 shares of common stock for consulting services, which were valued in the amount of $10,000. 2023 Transactions On December 8, 2023, the Company issued 50,000 shares of common stock for commitment shares as part of an Equity Financing Agreement, which were valued in the amount of $455. As of December 31, 2023 and December 31, 2022, the Company has 12,493,938 and 12,443,938 common shares issued and outstanding, respectively. Warrants During the year ended December 31, 2020, the Company issued warrants to purchase 16,000,000 shares of common stock, at exercise prices of $0.03 per share. These warrants expire three years from issuance date. The Company recorded the fair value of the 16,000,000 warrants issued with debt at approximately $279,867 at December 31, 2020 as a discount. On January 6, 2021, the Company issued warrants to purchase 10,000,000 shares of common stock, at exercise prices of $0.033 per share. These warrants expire three years from issuance date. The Company recorded the fair value of the 10,000,000 warrants issued with debt at approximately $237,811 as a discount. On June 22, 2021, the Company issued warrants to purchase 70,000,000 shares of common stock, at exercise prices of $0.100 per share. These warrants expire three years from issuance date. The Company recorded the fair value of the 70,000,000 warrants issued with debt at approximately $5,465,726 as a discount. The warrants were amended to change exercise date to June 22, 2023 and expire five years from exercise date. On September 20, 2021, the Company issued warrants to purchase 7,500,000 shares of common stock, at exercise prices of $0.085 per share. These warrants expire three years from issuance date. The Company recorded the fair value of the 7,500,000 warrants issued with debt at approximately $360,607 as a discount. The following table summarizes the Company’s warrant transactions during the year ended December 31, 2023 and year ended December 2022: Number of Weighted Outstanding at year ended December 31, 2021 103,500,000 $ 0.082 Granted - - Exercised - - Expired - - Outstanding at year ended December 31, 2022 103,500,000 $ 0.082 Granted - - Exercised - - Expired (16,000,000 ) -0.03 Outstanding at year ended December 31, 2023 87,500,000 $ 0.091 Warrants granted in the year ended December 31, 2020 were valued using the Black Scholes Merton Model with the risk-free interest rate of 0.20%, expected life 3 years, expected dividend rate of 0% and expected volatility ranging of 411.72%. Warrants granted in the year ended December 31, 2021 were valued using the Black Scholes Merton Model with the risk-free interest rate within ranges between 0.20% to 0.45%, term of 3 years, dividend rate of 0% and historical volatility ranging between, 338.36% to 394.78%. The final value assigned to the warrants was determined using a relative fair value calculation between the amount of warrants and promissory notes. Designation of Series AA Super Voting Preferred Stock On June 30, 2014, the Company filed with the Secretary of State with Nevada an amendment to the Company’s Articles of Incorporation, authorizing the issuance of up to eleven million (11,000,000) shares of preferred stock, par value $0.001 per share. On May 2, 2014, the Company filed with the Secretary of State with Nevada in the form of a Certificate of Designation that authorized the issuance of up to one million (1,000,000) shares of a new series of preferred stock, par value $0.001 per share, designated “Series AA Super Voting Preferred Stock,” for which the board of directors established the rights, preferences and limitations thereof. All of the Holders of the Series AA Super Voting Preferred Stock together, voting separately as a class, shall have an aggregate vote equal to sixty-seven (67%) percent of the total vote on all matters submitted to the stockholders that each stockholder of the Corporation’s Common Stock is entitled to vote at each meeting of stockholders of the Corporation (and written actions of stockholders in lieu of meetings) with respect to any and all matters presented to the stockholders of the Corporation for their action and consideration. The holders of the Series AA Super Voting Preferred Stock shall not be entitled to receive dividends paid on the Company’s common stock. Upon liquidation, dissolution and winding up of the affairs of the Company, whether voluntary or involuntary, the holders of the Series AA Super Voting Preferred Stock shall not be entitled to receive out of the assets of the Company, whether from capital or earnings available for distribution, any amounts which will be otherwise available to and distributed to the common shareholders. The shares of the Series AA Super Voting Preferred Stock will not be convertible into the shares of the Company’s common stock. On November 26, 2019, the Company filed with the Secretary of State with Nevada an amendment to the Company’s Articles of Incorporation, authorizing the increase to 1,050,000 shares of the Series AA Super Voting Preferred Stock. On June 26, 2020, Meso Numismatics, Inc. completed the repurchase of 1,000,000 shares of its Series AA (“Series AA”) Super Voting Preferred Stock for an aggregate total purchase price equal to $160,000, representing all of the Series AA shares held by E-Network de Costa Rica S.A. and S&M Chuah Enterprises Ltd., respectively. On June 26, 2020, due to Mr. Pereira’s resignation, Meso Numismatics, Inc.’s Board of Directors appointed Mr. David Christensen, current Director and President of the Company, to serve as Chief Executive Officer, Chief Financial Officer and Secretary, effective June 27, 2020 and granted 50,000 shares of Series AA to Mr. David Christensen. The $166,795 value of the 50,000 shares of Series AA Super Voting Preferred Stock to Mr. David Christensen is based on the 10,000 votes per preferred share to one vote per common share. Valuation based on definition of control premium is defined as the price to which a willing buyer and willing seller would agree in any arms-length transaction to acquire control of the Company. The premium paid above the market value of the company is real economic benefit to controlling the Company. Historically, the average control premium applied in M&A transactions averages approximately 30%, which represents the value of control. On August 18, 2021, Meso Numismatics, Inc., completed its acquisition of Global Stem Cells Group Inc., through a Stock Purchase Agreement acquiring all the outstanding capital stock of Global Stem Cells Group Inc and paid the purchase price of a total of 1,000,000 shares of Series AA Preferred Stock in the Company, 8,974 shares of Series DD Preferred Stock in the Company and $225,000 USD (the final payment of $50,000 was made on July 2, 2021). The Series AA Preferred shares issued on August 18, 2021, were valued based upon industry specific control premiums and the Company’s market cap at the time of the transaction. The $963,866 value of the 1,000,000 shares of Series AA Super Voting Preferred Stock issued to Benito Novas were valued based on a calculation by a third party independent valuation specialist. As of December 31, 2023 and December 31, 2022, the Company has 1,050,000 and 1,050,000 preferred shares of Series AA Preferred Stock issued and outstanding, respectively. During the period of these financial statements, no dividend was declared or paid on the Series AA preferred shares. Designation of Series BB Preferred Stock On March 29, 2017, the Company filed with the Secretary of State with Nevada in the form of a Certificate of Designation that authorized the issuance of up to one million (1,000,000) shares of a new series of preferred stock, par value $0.001 per share, designated “Series BB Preferred Stock,” for which the board of directors established the rights, preferences and limitations thereof. Each holder of outstanding shares of Series BB Preferred Stock shall be entitled to convert on a 1 for 1 basis into shares of the Company’s common stock, any or all of their shares of Series BB Preferred Stock after a minimum of six (6) months have elapsed from the issuance of the preferred stock to the holder. The Series BB Preferred Stock has no voting rights until the Holder redeems the preferred stock into the Company’s common stock. The Series BB Preferred Stock shall not be adjusted by the Corporation. The holders of the Series BB Preferred Stock shall not be entitled to receive dividends paid on the Company’s common stock. The Series BB Preferred Stock has a liquidation value of $1.00. Upon liquidation, dissolution and winding up of the affairs of the Company, whether voluntary or involuntary, the holders of the Series BB Preferred Stock shall be entitled to share equally and ratably in proportion to the preferred stock owned by the holder to receive out of the assets of the Company, whether from capital or earnings available for distribution, any amounts which will be otherwise available to and distributed to the common shareholders. As of December 31, 2019, 81,043 Preferred Series BB shares were exchanged for an aggregate of $97,252 convertible notes and 276,723 Preferred Series BB shares were exchanged for an aggregate of $332,068 promissory notes of which 78,620 were returned and cancelled and 279,146 were still outstanding at December 31, 2020. During the three months ended March 31, 2021, the remaining 279,146 were returned and cancelled. As of December 31, 2023 and December 31, 2022, the Company had no preferred shares of Series BB Preferred Stock issued and outstanding. Designation of Series CC Preferred Stock At any time prior to November 25, 2022 (“Automatic Conversion Date”) the Company may redeem for cash out of funds legally available therefor, any or all of the outstanding Series CC Convertible Preferred Stock at a price equal to $1,000 per share. If not converted prior, on the Automatic Conversion Date, any and all remaining issued and outstanding shares of Series CC Convertible Preferred Stock shall automatically convert at the Conversion Price, which is a price per share determined by dividing the number of issued and outstanding shares of common stock of the Company on the date of conversion by 1,000 and multiply the results by 0.8. Each holder of outstanding shares of Series CC Convertible Preferred Stock shall be entitled to convert, prior to the Automatic Conversion Date, part or all of its shares of Series CC Convertible Preferred Stock into a number of fully paid and nonassessable shares of common stock at a price per share determined by dividing the number of issued and outstanding shares of stock of the Company on the date of conversion by 1,000 and multiplying the results by 0.8 conversion price. The holders of the Series CC Convertible Preferred Stock shall not be entitled to receive dividends paid on the Company’s common stock. The holders of the Series CC Convertible Preferred Stock shall not be entitled to vote on any matter submitted to the shareholders of the Company for their vote, waiver, release or other action. As of December 31, 2023 and December 31, 2022, the Company had no preferred shares of Series CC Preferred Stock issued and outstanding. Designation of Series DD Convertible Preferred Stock On November 26, 2019, the Company filed with the Secretary of State with Nevada an amendment to the Company’s Articles of Incorporation, authorizing ten thousand (10,000) shares of a new series of preferred stock, par value $0.001 per share, designated “Series DD Convertible Preferred Stock,” for which the board of directors established the rights, preferences and limitations thereof. Each holder of outstanding shares of Series DD Convertible Preferred Stock shall be entitled to its shares of Series DD Convertible Preferred Stock into a number of fully paid and nonassessable shares of common stock determined by multiplying the number of issued and outstanding shares of common stock of the Company on the date of conversion by 3.17 conversion price. The holders of the Series DD Convertible Preferred Stock shall not be entitled to receive dividends paid on the Company’s common stock. The holders of the Series DD Convertible Preferred Stock shall not be entitled to vote on any matter submitted to the shareholders of the Company for their vote, waiver, release or other action. On August 18, 2021, Meso Numismatics, Inc., completed its acquisition of Global Stem Cells Group Inc., through a Stock Purchase Agreement acquiring all the outstanding capital stock of Global Stem Cells Group Inc and paid the purchase price of a total of 1,000,000 shares of Series AA Preferred Stock in the Company, 8,974 shares of Series DD Preferred Stock in the Company and $225,000 USD (the final payment of $50,000 was made on July 2, 2021). The $5,038,576 value of the 8,974 shares of Series DD Convertible Preferred Stock to Benito Novas is based on converting into a number of fully paid and nonassessable shares of common stock determined by multiplying the number of issued and outstanding shares of common stock of the Company on the date of conversion by 3.17 conversion price. The $5,038,576 value of the 8,974 shares of Series DD Convertible Preferred Stock represents the fair value of the consideration paid allocated to the assets and liabilities acquired from Global Stem Cells Group Inc. In consideration of mutual covenants set forth in the Professional Service Consulting Agreement, Dave Christensen, current Director, President, Chief Executive Officer, Chief Financial Officer and Secretary, shall be compensated monthly based on annual rate of $90,000, starting January 1, 2022. Additionally, the agreement includes an issuance of 896 shares of Series DD Preferred Stock of the Company. An amount of 448 shares were issued on August 18, 2021 and the remaining 448 were issued February 18, 2022. The $503,072 value of the 896 shares of Series DD Convertible Preferred Stock is based on converting into a number of fully paid and nonassessable shares of common stock determined by multiplying the number of issued and outstanding shares of common stock of the Company on the date of conversion by 3.17 conversion price. The $251,536 value of the 448 shares of Series DD Convertible Preferred Stock was recorded as stock payable at December 31, 2021 and issued on February 18, 2022. The full amount of $503,552 was expensed at the date of grant, as a matter of accounting policy. As of December 31, 2023 and December 31, 2022, the Company had 9,870 and 9,422 preferred shares of Series DD Convertible Preferred Stock issued and outstanding, respectively. During the period of these financial statements, no dividend was declared or paid on the Series DD preferred shares.

Related Party Transactions

Related Party Transactions	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 6 – RELATED PARTY TRANSACTIONS In consideration of mutual covenants set forth in the Professional Service Consulting Agreement, Dave Christensen, current Director, President, Chief Executive Officer, Chief Financial Officer and Secretary, shall be compensated monthly based on an annual rate of $90,000 starting January 1, 2022. Additionally, the agreement includes an issuance of 896 shares of Series DD Preferred Stock of the Company. An amount of 448 shares were issued on August 18, 2021 and the remaining 448 were issued on February 18, 2022. Amounts paid to Enterprise Technology Consulting, a Company 100% owned by Dave Christensen, CEO, for consulting services during the period ended June 30, 2024 and the year ended December 31, 2023 were $45,000 and $90,000, respectively. On August 18, 2021, through a Stock Purchase Agreement in which the Company acquired 100% of the outstanding shares of Global Stem Cell Group, Inc., the Company acquired a 2018 Jaguar F-Pace, which was acquired from Benito Novas for $45,000 on January 8, 2019 and assumed the related auto loan, with an original loan amount of $20,991 at 8.99% interest for 48 months and monthly payments of $504.94. As of June 30, 2024 and December 31, 2023, the principal balance of the outstanding auto loan was $0.00. Benito Novas’ brother, sister and nephew provide marketing/administrative and training/R&D services to Global Stem Cells Group and were paid $122,107 in the aggregate as consultants during the six months ended June 30, 2024, and $133,470 in the aggregate for the six months ended June 30, 2023.	NOTE 6 – RELATED PARTY TRANSACTIONS In consideration of mutual covenants set forth in the Professional Service Consulting Agreement, Dave Christensen, current Director, President, Chief Executive Officer, Chief Financial Officer and Secretary, shall be compensated monthly based on an annual rate of $90,000 starting January 1, 2022. Additionally, the agreement includes an issuance of 896 shares of Series DD Preferred Stock of the Company. An amount of 448 shares were issued on August 18, 2021 and the remaining 448 were issued on February 18, 2022. Amounts paid to Enterprise Technology Consulting, a Company 100% owned by Dave Christensen, CEO, for consulting services during the year ended December 31, 2023 and the year ended December 31, 2022 were $90,000 and $90,000, respectively. On August 18, 2021, through a Stock Purchase Agreement in which 100% of the outstanding shares of Global Stem Cell Group, Inc. the Company acquired a 2018 Jaguar F-Pace which was acquired from Benito Novas for $45,000 on January 8, 2019 and assumed the related auto loan, with an original loan amount of $20,991 at 8.99% interest for 48 months and monthly payments of $504.94. As of December 31, 2023 and December 31, 2022, the principal balance of the outstanding auto loan was $0.00. Benito Novas’ brother, sister and nephew provide marketing/administrative and training/R&D services to Global Stem Cells Group and were paid $233,893 in the aggregate as consultants during the year ended December 31, 2023, and $200,390 in the aggregate for the year ended December 31, 2022.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 7 – COMMITMENTS AND CONTINGENCIES Pursuant to an Agreement between Global Stem Cell Group and a lender dated November 17, 2020, in the event that any of Global Stem Cell Group, and/or the Entities and /or Parent (individually the “Company” and collectively the “Companies”) dispose of any assets to any party or third party or parties (an “Asset Disposition”), then Global Stem Cell Group shall undertake to cause such party, third party or parties to acquire the perpetual right of a percentage of Global revenues from the investor. The consideration for the right shall be equal to the fair value of the assets at the time of the Asset Disposition (the “Asset Disposition Payment”). The Asset Disposition Payment shall not exceed 27.5% (twenty-seven and a half percent) of the fair market value of the assets. During the period ending December 31, 2021, Global Stem Cell Group, Inc. entered into the Cancun lease with HELLIMEX, S.A. DE CV beginning January 16 2022 and ending on January 15, 2024. The property is located in the Tulum Trade Center, consisting of 1,647 square feet with a monthly rent of $2,714 and security deposit of $5,588. Due to the expansion of the Cancun Clinic, an additional 1,216 square feet Global Stem Cell Group, Inc. entered into a new Cancun lease with RIVIERA MAYA, S.A. DE C.V beginning January 16, 2024 and ending on January 15, 2026. The property is located in the Tulum Trade Center, consisting of 2,863 square feet with a monthly rent of $6,341 and a security deposit of $11,725. During the six months ended June 30, 2024 and the six months ended June 30, 2023 the Company paid $40,981 and $22,744, respectively in rent expense.	NOTE 7 – COMMITMENTS AND CONTINGENCIES Pursuant to an Agreement between Global Stem Cell Group and a lender dated November 17, 2020, in the event that any of Global Stem Cell Group, and/or the Entities and /or Parent (individually the “Company” and collectively the “Companies”) dispose of any Assets to any party or third party or parties (an “Asset Disposition”), then Global Stem Cell Group shall undertake to cause such party, third party or parties to acquire the perpetual right of a percentage of Global revenues from the Investor. The consideration for the Right shall be equal to the fair value (“FV”) of the Assets at the time of the Asset Disposition (the “Asset Disposition Payment”). The Asset Disposition Payment shall not exceed 27.5% (twenty-seven and a half percent) of the fair market value of the Assets. During the period ending December 31, 2021, Global Stem Cell Group, Inc. entered into the Cancun lease with HELLIMEX, S.A. DE CV beginning January 16 2022 and ending on January 15, 2024. The property is located in the Tulum Trade Center, consisting of 1,647 square feet with a monthly rent of $2,714 and security deposit of $5,588. During the year ended December 31, 2023 and the year ended December 31, 2022 the Company paid $53,451 and $44,097, respectively in rent expense.

Property and Equipment, Net

Property and Equipment, Net	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Property and Equipment, Net [Abstract]
PROPERTY AND EQUIPMENT, NET	NOTE 8 – PROPERTY AND EQUIPMENT, NET Property and equipment, net consisted of the following: June 30, December 31, Computer, equipment and vehicles (5 year useful life) $ 170,302 $ 166,774 Leasehold improvements (2 year useful life) 609,509 501,226 Less: accumulated depreciation (419,470 ) (308,697 ) Total property and equipment, net $ 360,341 $ 359,303 Depreciation expense for the six months ended June 30, 2024 and six months ended June 30, 2023 was $110,773 and $65,733, respectively. We evaluate the carrying value of long-lived assets for impairment on an annual basis or whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable. Further testing of specific assets or grouping of assets is required when undiscounted future cash flows associated with the assets is less than their carrying amounts. An asset is considered to be impaired when the anticipated undiscounted future cash flows of an asset group are estimated to be less than its carrying value. The amount of impairment recognized is the difference between the carrying value of the asset group and its fair value. Fair value estimates are based on assumptions concerning the amount and timing of estimated future cash flows. We recorded no impairment of long-lived assets for the period ended June 30, 2024 and the year ended December 31, 2023.	NOTE 8 – PROPERTY AND EQUIPMENT, NET Property and equipment, net consisted of the following: December 31, December 31, Computer and office equipment (5 year useful life) $ 166,774 $ 149,196 Leasehold improvements (2 year useful life) 501,226 133,208 Less: accumulated depreciation (308,697 ) (96,135 ) Total property and equipment, net $ 359,303 $ 186,269 Depreciation expense for the years ended December 31, 2023 and December 31, 2022 was $212,562 and $55,199, respectively. We evaluate the carrying value of long-lived assets for impairment on an annual basis or whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable. Further testing of specific assets or grouping of assets is required when undiscounted future cash flows associated with the assets is less than their carrying amounts. An asset is considered to be impaired when the anticipated undiscounted future cash flows of an asset group are estimated to be less than its carrying value. The amount of impairment recognized is the difference between the carrying value of the asset group and its fair value. Fair value estimates are based on assumptions concerning the amount and timing of estimated future cash flows. We recorded no impairment of long-lived assets for the year ended December 31, 2023 and the year ended December 31, 2022.

Intellectual Property

Intellectual Property	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Intellectual Property [Abstract]
INTELLECTUAL PROPERTY	NOTE 9 – INTELLECTUAL PROPERTY A third party independent valuation specialist was asked to determine the value of Global Stem Cell Group, Inc., tangible and intangible assets assuming the offering price was at fair value. In order to perform the purchase price allocation, the tangible and intangible assets were valued as of August 18, 2021. The Fair Value of the intangible assets as of the Valuation Date is reasonably represented as: June 30, December 31, Tradename - Trademarks $ 87,700 $ 87,700 Intellectual Property / Licenses 363,000 363,000 Customer Base 37,000 37,000 Intangible assets 487,700 487,700 Less: accumulated amortization (279,926 ) (231,156 ) Total intangible assets, net $ 207,774 $ 256,544 Amortization is computed on straight-line method based on estimated useful lives of 5 years. During the six months ended June 30, 2024 and the six months ended June 30, 2023, the Company recorded amortization expense of the intellectual property of $48,770 and $48,770, respectively.	NOTE 9 – INTELLECTUAL PROPERTY A third party independent valuation specialist was asked to determine the value of Global Stem Cell Group, Inc., tangible and intangible assets assuming the offering price was at fair value. In order to perform the purchase price allocation, the tangible and intangible assets were valued as of August 18, 2021. The Fair Value of the intangible assets as of the Valuation Date is reasonably represented as: December 31, December 31, Tradename - Trademarks $ 87,700 $ 87,700 Intellectual Property / Licenses 363,000 363,000 Customer Base 37,000 37,000 Intangible assets 487,700 487,700 Less: accumulated amortization (231,156 ) (133,616 ) Total intangible assets, net $ 256,544 $ 354,084 Amortization is computed on straight-line method based on estimated useful lives of 5 years. During the year ended December 31, 2023 and 2022, the Company recorded amortization expense of the intellectual property of $97,540 and $97,540, respectively.

Operating Leases

Operating Leases	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Operating Leases [Abstract]
OPERATING LEASES	NOTE 10 – OPERATING LEASES During the period ending December 31, 2021, Global Stem Cell Group, Inc. entered into the Cancun lease with HELLIMEX, S.A. DE CV beginning January 16, 2022 and ending on January 15, 2024. The property is located in the Tulum Trade Center, consisting of 1,647 square feet with a monthly rent of $2,714 and a security deposit of $5,588. In January 2022, the Company began the buildout of the clinic and began to order equipment. The Cancun facility was inaugurated in May 2022 and is accredited both by the Mexican General Health Council and Cofepris (Mexican FDA). Due to the expansion of the Cancun Clinic, an additional 1,216 square feet Global Stem Cell Group, Inc. entered into a new Cancun lease with RIVIERA MAYA, S.A. DE C.V beginning January 16, 2024 and ending on January 15, 2026. The property is located in the Tulum Trade Center, consisting of 2,863 square feet with a monthly rent of $6,341 and a security deposit of $11,725. The following table summarizes the Company’s undiscounted cash payment obligations for its non-cancelable lease liabilities through the end of the expected term of the lease: 2024 $ 38,046 2025 76,092 2026 — 2027 — 2028 — Total undiscounted cash payments 114,138 Less interest (5,980 ) Present value of payments $ 108,158	NOTE 11 – OPERATING LEASES During the period ending December 31, 2021, Global Stem Cell Group, Inc. entered into the Cancun lease with HELLIMEX, S.A. DE CV beginning January 16, 2022 and ending on January 15, 2024. The property is located in the Tulum Trade Center, consisting of 1,647 square feet with a monthly rent of $2,714 and a security deposit of $5,588. In January 2022, the Company began the buildout of the clinic and began to order equipment. The Cancun facility was inaugurated in May 2022 and is accredited both by the Mexican General Health Council and Cofepris (Mexican FDA). The following table summarizes the Company’s undiscounted cash payment obligations for its non-cancelable lease liabilities through the end of the expected term of the lease: 2024 $ 2,714 2025 - 2026 - 2027 - 2028 - Total undiscounted cash payments 2,714 Less interest - Present value of payments $ 2,714

Goodwill

Goodwill	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Goodwill [Abstract]
GOODWILL	NOTE 11 – GOODWILL On August 18, 2021, through a Stock Purchase Agreement, we acquired 100% of the outstanding shares of Global Stem Cell Group, Inc. for $225,000 in cash, the issuance of 1,000,000 shares of preferred series AA stock and the issuance of 8,974 shares of preferred series DD stock. The preliminary purchase price for the merger was determined to be $6.229 million, which consists of (i) 1 million shares of Series AA preferred stock valued at approximately $964,000, (ii) 8,974 shares of Series DD preferred stock valued at approximately $5.04 million and (iii) $225,000 in cash of which $175,000 was advanced prior to closing of the transaction. Under the acquisition method, the purchase price must be allocated to the reporting units net assets acquired, inclusive of intangible assets, with any excess fair value recorded to goodwill. The goodwill, which is not deductible for tax purposes, is attributable to the assembled workforce of Global Stem Cells Group, and the planned growth in new markets. The following table summarizes the Company’s carrying amount of goodwill during the six months ended June 30, 2024 and the year ended December 31, 2023: Goodwill Balance at December 31, 2022 $ 5,805,438 Acquisition - Impairment (4,125,460 ) Balance at December 31, 2023 $ 1,679,978 Acquisition - Impairment - Balance at June 30, 2024 $ 1,679,978 During each fiscal year, we periodically assess whether any indicators of impairment exist which would require us to perform an interim impairment review. As of each interim period end during each fiscal year, we concluded that a triggering event had not occurred that would more likely than not reduce the fair value of our reporting unit below their carrying values. We performed our annual test of goodwill for impairment as of December 31, 2023. The Company has recognized impairment of $4,125,460 and the Goodwill balance as of June 30, 2024 was $1,679,978.	NOTE 12 – GOODWILL On August 18, 2021, through a Stock Purchase Agreement, we acquired 100% of the outstanding shares of Global Stem Cell Group, Inc. for $225,000 in cash, the issuance of 1,000,000 shares of preferred series AA stock and the issuance of 8,974 shares of preferred series DD stock. The preliminary purchase price for the merger was determined to be $6.229 million, which consists of (i) 1 million shares of Series AA preferred stock valued at approximately $964,000, (ii) 8,974 shares of Series DD preferred stock valued at approximately $5.04 million and (iii) $225,000 in cash of which $175,000 was advanced prior to closing of the transaction. Under the acquisition method, the purchase price must be allocated to the reporting units net assets acquired, inclusive of intangible assets, with any excess fair value recorded to goodwill. The goodwill, which is not deductible for tax purposes, is attributable to the assembled workforce of Global Stem Cells Group, planned growth in new markets, and synergies expected to be achieved from the combined operations of Meso Numismatics, Inc. and Global Stem Cells Group. The following table summarizes the Company’s carrying amount of goodwill during the years ended December 31, 2023 and December 31, 2022: Goodwill Balance at December 31, 2021 $ 5,805,438 Acquisition - Impairment - Balance at December 31, 2022 $ 5,805,438 Acquisition - Impairment (4,125,460 ) Balance at December 31, 2023 $ 1,679,978 During each fiscal year, we periodically assess whether any indicators of impairment exist which would require us to perform an interim impairment review. As of each interim period end during each fiscal year, we concluded that a triggering event had not occurred that would more likely than not reduce the fair value of our reporting unit below their carrying values. We performed our annual test of goodwill for impairment as of December 31, 2023. The Company has recognized impairment of $4,125,460 and Goodwill balance as of December 31, 2023 is $1,679,978.

Subsequent Events

Subsequent Events	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 12 – SUBSEQUENT EVENTS In accordance with ASC 855-10, we have analyzed events and transactions that occurred subsequent to June 30, 2024 through the date these financial statements were issued and have determined that we do not have any other material subsequent events to disclose or recognize in these financial statements.	NOTE 14 – SUBSEQUENT EVENTS In accordance with ASC 855-10, we have analyzed events and transactions that occurred subsequent to December 31, 2023 through the date these financial statements were issued and have determined that we do not, aside from the following, have any other material subsequent events to disclose or recognize in these financial statements. The Company previously designated 1,000,000 shares of preferred stock as Series BB Preferred Stock and 8,000,000 shares of preferred stock as Series CC Preferred Stock. Effective on February 1, 2024, due to the fact that no shares of Series BB Preferred Stock or Series CC Preferred Stock were outstanding, the Board of Directors approved, and the Company filed, Certificates of Withdrawal of Certificate of Designations relating to such series of preferred stock with the Secretary of State of Nevada and terminated the designation of its Series BB Preferred Stock and Series CC Preferred Stock effective as of the same date. As a result, the only preferred stock which is currently designated by the Company is the Company’s Series AA Super Voting Preferred Stock and Series DD Preferred Stock. Due to the expansion of the Cancun Clinic, an additional 1,216 square feet Global Stem Cell Group, Inc. entered into a new Cancun lease with RIVIERA MAYA, S.A. DE C.V beginning January 16, 2024 and ending on January 15, 2026. The property is located in the Tulum Trade Center, consisting of 2,863 square feet with a monthly rent of $6,341 and a security deposit of $11,725.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2023
Income Taxes [Abstract]
INCOME TAXES	NOTE 10 – INCOME TAXES Due to the Company’s net losses, there were no provisions for income taxes for the years ended December 31, 2023 and 2022. The difference between the income tax expense of zero shown in the statement of operations and pre-tax book net loss times the federal statutory rate of 21% is due to the change in the valuation allowance. The benefit for income taxes differed from the amount computed using the U. S federal income tax rate of 21% for December 31, 2023, as follows 2023 Income tax (benefit) $ (2,060,870 ) Non-deductible 1,190,032 Change in valuation allowance 870,838 Income tax (benefit) per financial statements $ - Deferred income tax assets as of December 31, 2023 and 2022 were as follows: December 31, December 31, Deferred Tax Assets: Net operating losses $ 5,292,725 $ 4,421,887 Less valuation allowance (5,292,725 ) (4,421,887 ) Total deferred tax assets $ - $ - The Company has recorded a full allowance against its deferred tax assets as of December 31, 2023 and 2022 because management determined that it is not more-likely-than not that those assets will be realized. In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of deferred assets will not be realized. The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. For federal income tax purposes, the Company has a net operating loss carry forward of approximately $26,386,980 at December 31, 2023, which expires commencing in 2038.

Discontinued Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2023
Discontinued Operations [Abstract]
DISCONTINUED OPERATIONS	NOTE 13 – DISCONTINUED OPERATIONS On October 28, 2022, we entered into an Agreement of Conveyance, Transfer and Assignment of Subsidiary with our prior officer and director, Mr. Melvin Pereira, pursuant to which we agreed to sell Mr. Pereira 100% of our interest in Meso Numismatics Corp., a Florida corporation. In exchange, Mr. Pereira has agreed to assume all of the liabilities of Meso Numismatics, provide whatever financial and other materials needed by us to prepare and complete our financial statements for reporting purposes, and to not disparage our company. The Company reclassified the results of operations of the coins, paper currency, bullion and medals business resulting in a gain on discontinued operations of $68,313 for the year ended December 31, 2022. As a result of this transaction, we are no longer engaged in the sale of coins, paper currency, bullion and medals and we have moved into what we believe is a more lucrative opportunity for our company, the operations of Global Stem Cell Group. The following table presents the loss from discontinued operations for the year ended December 31, 2022: Revenue $ 24,991 Cost of revenue 23,024 Gross profit 1,967 Operating expenses Advertising and marketing 117 Depreciation and amortization expense 1,400 General and administrative (67,864 ) Total operating expenses (66,347 ) Gain from discontinued operations $ 68,313

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Summary of Significant Accounting Policies [Abstract]
Principles of Consolidation and Basis of Presentation	Principles of Consolidation and Basis of Presentation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Global Stem Cells Group Inc. (since August 18, 2021) and Cellular Hope Institute, wholly-owned subsidiary of Global Stem Cells Group Inc. These condensed consolidated financial statements have been prepared and, in the opinion of management, contain all the adjustments (consisting of those of a normal recurring nature) considered necessary to present fairly the consolidated financial position and the consolidated statements of income and consolidated cash flows for the periods presented in conformity with generally accepted accounting principles for interim consolidated financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X, Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America. Operating results for the three months ended March 31, 2024 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2024. It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2023, filed on April 15, 2024, which can be found at www.sec.gov. All significant intercompany transactions have been eliminated in consolidation.	Principles of Consolidation and Basis of Presentation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Global Stem Cells Group Inc. (since August 18, 2021) and Cellular Hope Institute, wholly-owned subsidiary of Global Stem Cells Group Inc. All significant intercompany transactions have been eliminated in consolidation.
Use of Estimates in Financial Statement Presentation	Use of Estimates in Financial Statement Presentation The preparation of these financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The significant estimates included in these financial statements are associated with accounting for the goodwill, derivative liability, valuation of preferred stock, and for the valuation of assets and liabilities in business combination.	Use of Estimates in Financial Statement Presentation The preparation of these financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The significant estimates included in these financial statements are associated with accounting for the goodwill, derivative liability, valuation of preferred stock, and for the valuation of assets and liabilities in business combination.
Reclassifications	Reclassifications Certain amounts for the prior year have been revised or reclassified to conform to the current year presentation. No change in net loss resulted from these reclassifications.	Reclassifications Certain amounts for the prior year have been revised or reclassified to conform to the current year presentation. No change in net loss resulted from these reclassifications.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid accounts with original maturities of three months or less to be cash equivalents. At June 30, 2024 and December 31, 2023, all of the Company’s cash was deposited in major banking institutions. There were no cash equivalents as of June 30, 2024 and December 31, 2023. Our cash balances at financial institutions may exceed the Federal Deposit Insurance Company’s (FDIC) insured limit of $250,000 from time to time.	Cash and Cash Equivalents The Company considers all highly liquid accounts with original maturities of three months or less to be cash equivalents. At December 31, 2023 and December 31, 2022, all of the Company’s cash was deposited in major banking institutions. There were no cash equivalents as of December 31, 2023 and December 31, 2022. Our cash balances at financial institutions may exceed the Federal Deposit Insurance Company’s (FDIC) insured limit of $250,000 from time to time.
Accounts Receivable	Accounts Receivable Accounts receivable are recorded at original invoice amount less an allowance for uncollectible accounts that management believes will be adequate to absorb estimated losses on existing balances. Management estimates the allowance based on collectability of accounts receivable and prior bad debt experience. Accounts receivable balances are written off against the allowance upon management’s determination that such accounts are uncollectible. Recoveries of accounts receivable previously written off are recorded when received. Management believes that credit risks on accounts receivable will not be material to the financial position of the Company or results of operations. The allowance for doubtful accounts was $0 and $0 as of June 30, 2024 and December 31, 2023, respectively.	Accounts Receivable Accounts receivable are recorded at original invoice amount less an allowance for uncollectible accounts that management believes will be adequate to absorb estimated losses on existing balances. Management estimates the allowance based on collectability of accounts receivable and prior bad debt experience. Accounts receivable balances are written off against the allowance upon management’s determination that such accounts are uncollectible. Recoveries of accounts receivable previously written off are recorded when received. Management believes that credit risks on accounts receivable will not be material to the financial position of the Company or results of operations. The allowance for doubtful accounts was $0 and $0 as of December 31, 2023 and December 31, 2022, respectively.
Intangible Assets	Intangible Assets Intangible assets with finite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are not amortized, but are tested for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. No impairment was recognized for the three months ended June 30, 2024 and the year ended December 31, 2023.	Intangible Assets Intangible assets with finite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are not amortized, but are tested for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. No impairment was recognized for the year ended December 31, 2023 and the year ended December 31, 2022.
Lease Accounting	Lease Accounting The Company leases office space and clinical space under a lease arrangement. These properties are generally leased under non-cancelable agreements that contain lease terms in excess of twelve months on the date of entry as well as renewal options for additional periods. The agreements, which have been classified as operating leases, generally provide for base minimum rental payment, as well non-lease components including insurance, taxes, maintenance, and other common area costs. At the lease commencement date, the Company recognizes a right-of-use asset and a lease liability for all leases, except short-term leases with an original term of twelve months or less. The right-of-use asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease. The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any prepayments to the lessor and initial direct costs such as brokerage commissions, less any lease incentives received. All right-of-use assets are periodically reviewed for impairment in accordance with standards that apply to long-lived assets. The lease liability is initially measured at the present value of the lease payments, discounted using the rate implicit in the contract if available or an estimate of our incremental borrowing rate for a collateralized loan with the same term as the underlying lease. The discount rates used for the initial measurement of lease liabilities as of the date of entry were based on the original lease terms. Lease payments included in the measurement of lease liabilities consist of (i) fixed lease payments for the non-cancelable lease term, (ii) fixed lease payments for optional renewal periods where it is reasonably certain the renewal option will be exercised, and (iii) variable lease payments that depend on an underlying index or rate, based on the index or rate in effect at lease commencement. Certain real estate lease agreements require payments for non-lease costs such as utilities and common area maintenance. The Company has elected an accounting policy to not separate implicit components of the contract that may be considered non-lease related. Lease expense for operating leases consists of the fixed lease payments recognized on a straight-line basis over the lease term plus variable lease payments as incurred. The lease payments are allocated between a reduction of the lease liability and interest expense. Depreciation of the right-of-use asset for operating leases reflects the use of the asset on straight-line basis over the expected term of the lease.
Goodwill	Goodwill We test our reporting unit for impairment annually at year end or more frequently if events or circumstances indicate it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the carrying amount of a reporting unit exceeds its estimated fair value, we record an impairment loss based on the difference between fair value and carrying amount of the reporting unit, not to exceed to the associated carrying amount of goodwill. (see Note 11 for detail of goodwill).	Goodwill We test our reporting unit for impairment annually at year end or more frequently if events or circumstances indicate it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the carrying amount of a reporting unit exceeds its estimated fair value, we record an impairment loss based on the difference between fair value and carrying amount of the reporting unit, not to exceed to the associated carrying amount of goodwill. (see Note 12 for detail of goodwill).
Derivative Instruments	Derivative Instruments The derivative instruments are accounted for as liabilities, the derivative instrument is initially recorded at its fair market value and is then re-valued at each reporting date, with changes in fair value recognized in operations for each reporting period. The Company uses the Monte Carlo option pricing model to value the derivative instruments.	Derivative Instruments The derivative instruments are accounted for as liabilities, the derivative instrument is initially recorded at its fair market value and is then re-valued at each reporting date, with changes in fair value recognized in operations for each reporting period. The Company uses the Monte Carlo option pricing model to value the derivative instruments.
Revenue Recognition	Revenue Recognition The Company recognizes revenue from the sale of products under ASC 606 by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. The Company recognizes revenue when it satisfies a performance obligation by transferring control over a product to a customer or services are provided. Revenue is measured based on the consideration the Company receives in exchange for those products.	Revenue Recognition The Company recognizes revenue from the sale of products under ASC 606 by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. The Company recognizes revenue when it satisfies a performance obligation by transferring control over a product to a customer or services are provided. Revenue is measured based on the consideration the Company receives in exchange for those products.
Income Taxes	Income Taxes The Company uses the liability method to record income tax activity. Deferred taxes are determined based upon the estimated future tax effects of differences between the financial reporting and tax reporting bases of assets and liabilities, given the provisions of currently enacted tax laws. The accounting for uncertainty in income taxes recognized in an enterprise’s financial statements uses the threshold of more-likely-than-not to be sustained upon examination for inclusion or exclusion. Measurement of the tax uncertainty occurs if the recognition threshold has been met.	Income Taxes The Company uses the liability method to record income tax activity. Deferred taxes are determined based upon the estimated future tax effects of differences between the financial reporting and tax reporting bases of assets and liabilities, given the provisions of currently enacted tax laws. The accounting for uncertainty in income taxes recognized in an enterprise’s financial statements uses the threshold of more-likely-than-not to be sustained upon examination for inclusion or exclusion. Measurement of the tax uncertainty occurs if the recognition threshold has been met.
Net Earnings (Losses) Per Common Share	Net Earnings (Losses) Per Common Share The Company accounts for net loss per share in accordance with Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”), which requires presentation of basic and diluted earnings per share (“EPS”) on the face of the statement of operations for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS. Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during each period. It excludes the dilutive effects of any potentially issuable common shares. The effect of common stock equivalents is anti-dilutive with respect to losses and therefore basic and dilutive is the same. Diluted net loss per share is calculated by including any potentially dilutive share issuances in the denominator. The following securities are excluded from the calculation of weighted average diluted shares at June 30, 2024 and December 31, 2023, respectively, because their inclusion would have been anti-dilutive. June 30, December 31, 2024 2023 Convertible notes outstanding 124,343 293,973 Convertible preferred stock outstanding 39,090,908 39,090,908 Shares underlying warrants outstanding 7,500,000 87,500,000 46,715,251 126,884,881	Net Earnings (Losses) Per Common Share The Company accounts for net loss per share in accordance with Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”), which requires presentation of basic and diluted earnings per share (“EPS”) on the face of the statement of operations for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS. Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during each period. It excludes the dilutive effects of any potentially issuable common shares. The effect of common stock equivalents is anti-dilutive with respect to losses and therefore basic and dilutive is the same. Diluted net loss per share is calculated by including any potentially dilutive share issuances in the denominator. The following securities are excluded from the calculation of weighted average diluted shares at December 31, 2023 and 2022, respectively, because their inclusion would have been anti-dilutive. For the Years Ended 2023 2022 Convertible notes outstanding 293,973 365,463 Convertible preferred stock outstanding 39,090,908 39,447,283 Shares underlying warrants outstanding 87,500,000 103,500,000 126,884,881 143,312,746
Fair Value of Financial Instruments	Fair Value of Financial Instruments The fair value of financial instruments, which include cash, accounts payable and accrued expenses and advances from related parties were estimated to approximate their carrying values due to the immediate or short-term maturity of these financial instruments. Management is of the opinion that the Company is not exposed to significant interest, currency or credit risks arising from financial instruments. Fair value is defined as the price which would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-tier fair value hierarchy which prioritizes the inputs used in the valuation methodologies is as follows: Level 1 Inputs - Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 2 Inputs - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means. Level 3 Inputs - Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity’s own assumptions about the assumptions that market participants would use in pricing the assets or liabilities. At June 30, 2024 and December 31, 2023, the carrying amounts of the Company’s financial instruments, including cash, account payables, and accrued expenses, approximate their respective fair value due to the short-term nature of these instruments. At June 30, 2024 and December 31, 2023, the Company does not have any assets or liabilities except for derivative liabilities related to convertible notes payable required to be measured at fair value in accordance with FASB ASC Topic 820, Fair Value Measurement. The following presents the Company’s fair value hierarchy for those assets and liabilities measured at fair value as of June 30, 2024 and December 31, 2023: Level 1 Level 2 Level 3 Total June 30, 2024 Derivative liability - - 4,352 4,352 Total $ - $ - $ 4,352 $ 4,352 December 31, 2023 Derivative liability - - 2,146 2,146 Total $ - $ - $ 2,146 $ 2,146	Fair Value of Financial Instruments The fair value of financial instruments, which include cash, accounts payable and accrued expenses and advances from related parties were estimated to approximate their carrying values due to the immediate or short-term maturity of these financial instruments. Management is of the opinion that the Company is not exposed to significant interest, currency or credit risks arising from financial instruments. Fair value is defined as the price which would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-tier fair value hierarchy which prioritizes the inputs used in the valuation methodologies is as follows: Level 1 Inputs - Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 2 Inputs - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means. Level 3 Inputs - Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity’s own assumptions about the assumptions that market participants would use in pricing the assets or liabilities. At December 31, 2023 and December 31, 2022, the carrying amounts of the Company’s financial instruments, including cash, account payables, and accrued expenses, approximate their respective fair value due to the short-term nature of these instruments. At December 31, 2023 and December 31, 2022, the Company does not have any assets or liabilities except for derivative liabilities related to convertible notes payable required to be measured at fair value in accordance with FASB ASC Topic 820, Fair Value Measurement. The following presents the Company’s fair value hierarchy for those assets and liabilities measured at fair value as of December 31, 2023 and December 31, 2022: Level 1 Level 2 Level 3 Total December 31, 2023 Derivative liability 2,146 2,146 Total $ - $ - $ 2,146 $ 2,146 December 31, 2022 Derivative liability 6,944 6,944 Total $ - $ - $ 6,944 $ 6,944
Comprehensive Income	Comprehensive Income The Company records comprehensive income as the change in equity of a business during a period from transactions and other events and circumstances from non-owner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners. Other comprehensive income (loss) includes foreign currency translation adjustments and unrealized gains and losses on available-for-sale securities. As of June 30 , 2024 and December 31, 2023, the Company had no items that represent comprehensive loss and, therefore, has not included a schedule of comprehensive loss in the financial statements.	Comprehensive Income The Company records comprehensive income as the change in equity of a business during a period from transactions and other events and circumstances from non-owner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners. Other comprehensive income (loss) includes foreign currency translation adjustments and unrealized gains and losses on available-for-sale securities. As of , 2023 and December 31, 2022, the Company had no items that represent comprehensive loss and, therefore, has not included a schedule of comprehensive loss in the financial statements.
Stock Based Compensation	Stock Based Compensation Share-based compensation issued to employees is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period. The Company measures the fair value of the share-based compensation issued to non-employees at the grant date using the stock price observed in the trading market (for stock transactions) or the fair value of the award (for non-stock transactions), which were considered to be more reliably determinable measures of fair value than the value of the services being rendered.	Stock Based Compensation Share-based compensation issued to employees is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period. The Company measures the fair value of the share-based compensation issued to non-employees at the grant date using the stock price observed in the trading market (for stock transactions) or the fair value of the award (for non-stock transactions), which were considered to be more reliably determinable measures of fair value than the value of the services being rendered.
New Accounting Pronouncements	New Accounting Pronouncements In March 2020, No. 2020 04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting 2020 04 January 2021, 2021 01, Reference Rate Reform Scope December 2022, 2022 06, Reference Rate Reform Deferral of the Sunset Date of Topic 848 2020 04 December 31, 2024. not In June 2016, No. 2016 13, Financial Instruments Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments 2016 13 November 19, 2019, 2016 13 December 15, 2023, Other accounting standards and amendments to existing accounting standards that have been issued and have future effective dates are not applicable or are not expected to have a significant impact on the Company’s consolidated financial statements	New Accounting Pronouncements In March 2020, No. 2020 04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting 2020 04 January 2021, 2021 01, Reference Rate Reform Scope December 2022, 2022 06, Reference Rate Reform Deferral of the Sunset Date of Topic 848 2020 04 December 31, 2024. not In June 2016, No. 2016 13, Financial Instruments Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments 2016 13 November 19, 2019, 2016 13 December 15, 2023, Other accounting standards and amendments to existing accounting standards that have been issued and have future effective dates are not applicable or are not expected to have a significant impact on the Company’s consolidated financial statements
Going Concern	Going Concern The financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses since inception, resulting in an accumulated deficit of $66,027,771 and a working capital deficit of $25,730,147 as of June 30, 2024 and future losses are anticipated. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue its operations as a going concern is dependent on management’s plans, which include the raising of capital through debt and/or equity markets with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The Company will require additional funding to finance the growth of its current and expected future operations as well to achieve its strategic objectives. There can be no assurance that financing will be available in amounts or terms acceptable to the Company, if at all. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.	Going Concern The financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses since inception, resulting in an accumulated deficit of $61,990,131 and a working capital deficit of $21,674,139 as of December 31, 2023 and future losses are anticipated. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue its operations as a going concern is dependent on management’s plans, which include the raising of capital through debt and/or equity markets with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The Company will require additional funding to finance the growth of its current and expected future operations as well to achieve its strategic objectives. There can be no assurance that financing will be available in amounts or terms acceptable to the Company, if at all. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Summary of Significant Accounting Policies [Abstract]
Schedule of Weighted Average Diluted Shares	The following securities are excluded from the calculation of weighted average diluted shares at June 30, 2024 and December 31, 2023, respectively, because their inclusion would have been anti-dilutive. June 30, December 31, 2024 2023 Convertible notes outstanding 124,343 293,973 Convertible preferred stock outstanding 39,090,908 39,090,908 Shares underlying warrants outstanding 7,500,000 87,500,000 46,715,251 126,884,881	The following securities are excluded from the calculation of weighted average diluted shares at December 31, 2023 and 2022, respectively, because their inclusion would have been anti-dilutive. For the Years Ended 2023 2022 Convertible notes outstanding 293,973 365,463 Convertible preferred stock outstanding 39,090,908 39,447,283 Shares underlying warrants outstanding 87,500,000 103,500,000 126,884,881 143,312,746
Schedule of Fair Value Hierarchy for those Assets and Liabilities	The following presents the Company’s fair value hierarchy for those assets and liabilities measured at fair value as of June 30, 2024 and December 31, 2023: Level 1 Level 2 Level 3 Total June 30, 2024 Derivative liability - - 4,352 4,352 Total $ - $ - $ 4,352 $ 4,352 December 31, 2023 Derivative liability - - 2,146 2,146 Total $ - $ - $ 2,146 $ 2,146	The following presents the Company’s fair value hierarchy for those assets and liabilities measured at fair value as of December 31, 2023 and December 31, 2022: Level 1 Level 2 Level 3 Total December 31, 2023 Derivative liability 2,146 2,146 Total $ - $ - $ 2,146 $ 2,146 December 31, 2022 Derivative liability 6,944 6,944 Total $ - $ - $ 6,944 $ 6,944

Revenue Recognition (Tables)

Revenue Recognition (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Revenue Recognition [Abstract]
Schedule of Revenue by Product Category	The following table presents the Company’s revenue by product category for the six months ended June 30, 2024 and 2023: For the Six Months Ended 2024 2023 Training $ 267,827 $ 291,464 Product supplies 769,237 629,456 Equipment 102,060 109,740 Patient procedures 471,259 116,897 Total revenue $ 1,610,363 $ 1,147,557	The following table presents the Company’s revenue by product category for the years ended December 31, 2023 and 2022: For the Years Ended 2023 2022 Training $ 599,425 $ 279,404 Product supplies 1,329,159 866,104 Equipment 162,370 163,460 Patient procedures 318,999 221,255 Total revenue $ 2,409,953 $ 1,530,223
Schedule of Revenues, Cost of Revenues, Gross Profits, Assets and Net Profit (Loss)	Listed below are the revenues, cost of revenues, gross profits, assets and net profit (loss) by Company: For the Six Months Ended June 30, 2024 Global Stem Meso Cells Group Numismatics Total Revenue $ 1,610,363 $ - $ 1,639,863 Cost of revenue 514,488 - 514,488 Gross profit $ 1,095,875 $ - $ 1,125,375 Gross Profit % 68.05 % 0.00 % 68.63 % Assets $ 1,168,726 $ 1,910,860 $ 3,079,586 Net profit (loss) $ (104,647 ) $ (3,932,993 ) $ (4,037,640 )	Listed below are the revenues, cost of revenues, gross profits, assets and net loss by Company: For the Year Ended December 31, 2023 Global Stem Meso Cells Group Numismatics Total Revenue $ 2,409,953 $ - $ 2,409,953 Cost of revenue 734,285 - 734,285 Gross profit $ 1,675,668 $ - $ 1,675,668 Gross Profit % 69.53 % 0.00 % 69.53 % Assets $ 908,171 $ 1,970,932 $ 2,879,103 Net loss $ (323,109 ) $ (9,490,557 ) $ (9,813,666 )

Notes Payable (Tables)

Notes Payable (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Notes Payable [Abstract]
Schedule of Convertible Notes	The balance of the convertible notes as of June 30, 2024 and December 31, 2023 is as follows: June 30, December 31, 2024 2023 Convertible notes payable $ 44,939 $ 57,252 Less: Discount (4,958 ) (9,916 ) Convertible notes payable, net $ 39,981 $ 35,023	The balance of the convertible notes as of December 31, 2023 and December 31, 2022 is as follows: December 31, December 31, 2023 2022 Convertible notes payable $ 44,939 $ 57,252 Less: Discount 9,916 19,833 Convertible notes payable, net $ 35,023 $ 37,419
Schedule of Promissory Notes	The balance of the promissory notes as of June 30, 2024 and December 31, 2023 is as follows: June 30, December 31, 2024 2023 Promissory notes payable $ 19,722,931 $ 19,722,931 Promissory notes payable-related party 7,800 7,800 Less: Discount (65,506 ) (2,100,966 ) Less: Deferred finance costs - (15,798 ) Promissory notes payable, net $ 19,665,225 $ 17,613,966	The balance of the promissory as of December 31, 2023 and December 31, 2022 is as follows: December 31, December 31, 2023 2022 Promissory notes payable $ 19,730.731 $ 20,237,559 Less: Discount 2,100,966 5,117,631 Less: Deferred finance costs 15,798 49,132 Promissory notes payable, net $ 17,613,966 $ 15,070,796
Schedule of Fair Values of the Embedded Convertible Notes Derivatives and Tainted Convertible Notes Using the Lattice Valuation	The Company determined the fair values of the embedded convertible notes derivatives and tainted convertible notes using the lattice valuation model with the following assumptions: June 30, 2024 Common stock issuable 124,343 Market value of common stock on measurement date $ 0.035 Adjusted exercise price $ 0.06 Risk free interest rate 5.01 % Instrument lives in years 0.50 Year Expected volatility 99.80 % Expected dividend yields None	The Company determined the fair values of the embedded convertible notes derivatives and tainted convertible notes using the lattice valuation model with the following assumptions: December 31, 2023 Common stock issuable 293,973 Market value of common stock on measurement date $0.0073 Adjusted exercise price $0.06 Risk free interest rate 4.75% Instrument lives in years 1.00 Year Expected volatility 83% Expected dividend yields None
Schedule of Fair Value of the Derivative Liability	The balance of the fair value of the derivative liability as of June 30, 2024 and December 31, 2023 is as follows: Balance at December 31, 2022 $ 6,944 Additions - Fair value loss (3,450 ) Conversions (1,348 ) Balance at December 31, 2023 2,146 Additions - Fair value loss 2,206 Conversions - Balance at June 30, 2024 $ 4,352	The balance of the fair value of the derivative liability as of December 31, 2023 and December 31, 2022 is as follows: Balance at December 31, 2021 $ 20,442 Additions - Fair value loss (10,856 ) Conversions (2,642 Balance at December 31, 2022 6,944 Additions - Fair value gain (3,450 ) Conversions (1,348 ) Balance at December 31, 2023 $ 2,146

Stockholders Equity (Tables)

Stockholders Equity (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Stockholders Equity [Line Items]
Schedule of Warrant Transactions	The following table summarizes the Company’s warrant transactions during the six months ended June 30, 2024 and the year ended December 31, 2023: Number of Weighted Outstanding at year ended December 31, 2022 103,500,000 $ 0.082 Granted - - Exercised - - Expired (16,000,000 ) -0.03 Outstanding at year ended December 31, 2023 87,500,000 $ 0.091 Granted - - Exercised - - Expired (80,000,000 ) -0.092 Outstanding at quarter ended June 30, 2024 7,500,000 $ 0.091	The following table summarizes the Company’s warrant transactions during the year ended December 31, 2023 and year ended December 2022: Number of Weighted Outstanding at year ended December 31, 2021 103,500,000 $ 0.082 Granted - - Exercised - - Expired - - Outstanding at year ended December 31, 2022 103,500,000 $ 0.082 Granted - - Exercised - - Expired (16,000,000 ) -0.03 Outstanding at year ended December 31, 2023 87,500,000 $ 0.091

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Property and Equipment, Net [Abstract]
Schedule of Property and Equipment, Net	Property and equipment, net consisted of the following: June 30, December 31, Computer, equipment and vehicles (5 year useful life) $ 170,302 $ 166,774 Leasehold improvements (2 year useful life) 609,509 501,226 Less: accumulated depreciation (419,470 ) (308,697 ) Total property and equipment, net $ 360,341 $ 359,303	Property and equipment, net consisted of the following: December 31, December 31, Computer and office equipment (5 year useful life) $ 166,774 $ 149,196 Leasehold improvements (2 year useful life) 501,226 133,208 Less: accumulated depreciation (308,697 ) (96,135 ) Total property and equipment, net $ 359,303 $ 186,269

Intellectual Property (Tables)

Intellectual Property (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Intellectual Property [Abstract]
Schedule of Fair Value of the Intangible Assets	The Fair Value of the intangible assets as of the Valuation Date is reasonably represented as: June 30, December 31, Tradename - Trademarks $ 87,700 $ 87,700 Intellectual Property / Licenses 363,000 363,000 Customer Base 37,000 37,000 Intangible assets 487,700 487,700 Less: accumulated amortization (279,926 ) (231,156 ) Total intangible assets, net $ 207,774 $ 256,544	The Fair Value of the intangible assets as of the Valuation Date is reasonably represented as: December 31, December 31, Tradename - Trademarks $ 87,700 $ 87,700 Intellectual Property / Licenses 363,000 363,000 Customer Base 37,000 37,000 Intangible assets 487,700 487,700 Less: accumulated amortization (231,156 ) (133,616 ) Total intangible assets, net $ 256,544 $ 354,084

Operating Leases (Tables)

Operating Leases (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Operating Leases [Abstract]
Schedule of Undiscounted Cash Payment Obligations for Its Non-Cancelable Lease Liabilities	The following table summarizes the Company’s undiscounted cash payment obligations for its non-cancelable lease liabilities through the end of the expected term of the lease: 2024 $ 38,046 2025 76,092 2026 — 2027 — 2028 — Total undiscounted cash payments 114,138 Less interest (5,980 ) Present value of payments $ 108,158	The following table summarizes the Company’s undiscounted cash payment obligations for its non-cancelable lease liabilities through the end of the expected term of the lease: 2024 $ 2,714 2025 - 2026 - 2027 - 2028 - Total undiscounted cash payments 2,714 Less interest - Present value of payments $ 2,714

Goodwill (Tables)

Goodwill (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Goodwill [Abstract]
Schedule of Goodwill	The following table summarizes the Company’s carrying amount of goodwill during the six months ended June 30, 2024 and the year ended December 31, 2023: Goodwill Balance at December 31, 2022 $ 5,805,438 Acquisition - Impairment (4,125,460 ) Balance at December 31, 2023 $ 1,679,978 Acquisition - Impairment - Balance at June 30, 2024 $ 1,679,978	The following table summarizes the Company’s carrying amount of goodwill during the years ended December 31, 2023 and December 31, 2022: Goodwill Balance at December 31, 2021 $ 5,805,438 Acquisition - Impairment - Balance at December 31, 2022 $ 5,805,438 Acquisition - Impairment (4,125,460 ) Balance at December 31, 2023 $ 1,679,978

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Income Taxes [Abstract]
Schedule of Amount Computed Using the U. S Federal Income Tax Rate	The benefit for income taxes differed from the amount computed using the U. S federal income tax rate of 21% for December 31, 2023, as follows 2023 Income tax (benefit) $ (2,060,870 ) Non-deductible 1,190,032 Change in valuation allowance 870,838 Income tax (benefit) per financial statements $ -
Schedule of Deferred Income Tax Assets	Deferred income tax assets as of December 31, 2023 and 2022 were as follows: December 31, December 31, Deferred Tax Assets: Net operating losses $ 5,292,725 $ 4,421,887 Less valuation allowance (5,292,725 ) (4,421,887 ) Total deferred tax assets $ - $ -

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2023
Discontinued Operations [Abstract]
Schedule of Loss from Discontinued Operations	The following table presents the loss from discontinued operations for the year ended December 31, 2022: Revenue $ 24,991 Cost of revenue 23,024 Gross profit 1,967 Operating expenses Advertising and marketing 117 Depreciation and amortization expense 1,400 General and administrative (67,864 ) Total operating expenses (66,347 ) Gain from discontinued operations $ 68,313

Organization and Description _2

Organization and Description of Business (Details) - USD ($)					6 Months Ended	12 Months Ended
	Aug. 18, 2021	Jul. 02, 2021	Dec. 31, 2019	Aug. 04, 2017	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022	Oct. 28, 2022	Nov. 03, 2021	Nov. 16, 2016
Organization and Description of Business (Details) [Line Items]
Reverse stock split, description					On July 2, 2018, the Board of Directors authorized and shareholders approved a 1-for-1,000 reverse stock split of the Company’s issued and outstanding shares of common stock held by the holders of record.	On July 2, 2018, the Board of Directors authorized and shareholders approved a 1-for-1,000 reverse stock split of its issued and outstanding shares of common stock held by the holders of record. The prior year financials have been changed to reflect the 1-for-1,000 reverse stock split.
Lans Holdings Inc [Member]
Organization and Description of Business (Details) [Line Items]
Escrow									$ 8,200,000
Series of Individually Immaterial Business Acquisitions [Member]
Organization and Description of Business (Details) [Line Items]
Purchase price		$ 50,000
Gain on discontinued operations							$ 68,313
Mr Melvin Pereira [Member] | Series of Individually Immaterial Business Acquisitions [Member]
Organization and Description of Business (Details) [Line Items]
Interest percentage								100%
Series BB Preferred Stock [Member]
Organization and Description of Business (Details) [Line Items]
Number of shares issued (in Shares)			81,043	25,000
Series BB Preferred Stock [Member] | Series of Individually Immaterial Business Acquisitions [Member]
Organization and Description of Business (Details) [Line Items]
Percentage of ownership interest				100%						100%
Series BB Preferred Stock [Member] | Meso Numismatics [Member]
Organization and Description of Business (Details) [Line Items]
Share issued (in Shares)				25,000
Series AA Preferred Stock [Member]
Organization and Description of Business (Details) [Line Items]
Share issued (in Shares)					1,050,000	1,050,000	1,050,000
Series AA Preferred Stock [Member] | Series of Individually Immaterial Business Acquisitions [Member]
Organization and Description of Business (Details) [Line Items]
Number of shares issued (in Shares)	1,000,000
Series DD Preferred Stock [Member]
Organization and Description of Business (Details) [Line Items]
Number of shares issued (in Shares)					8,974	8,974
Series DD Preferred Stock [Member] | Series of Individually Immaterial Business Acquisitions [Member]
Organization and Description of Business (Details) [Line Items]
Number of shares issued (in Shares)	8,974
Purchase price	$ 225,000
Series CC Preferred Stock [Member] | Series of Individually Immaterial Business Acquisitions [Member] | Lans Holdings Inc [Member]
Organization and Description of Business (Details) [Line Items]
Number of shares issued (in Shares)					1,000	1,000
Common Stock [Member] | Lans Holdings Inc [Member]
Organization and Description of Business (Details) [Line Items]
Escrow					$ 8,200,000	$ 8,200,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023		Dec. 31, 2022
Summary of Significant Accounting Policies [Abstract]
Federal deposit insurance	$ 250,000	$ 250,000
Allowance for doubtful accounts	0	0		$ 0
Accumulated deficit	(66,027,771)	(61,990,131)	[1]	$ (52,176,465)
Working capital deficit	$ 25,730,147	$ 21,674,139
[1] Derived from audited information

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of Weighted Average Diluted Shares - shares	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Weighted Average Diluted Shares [Line Items]
Weighted average diluted shares	46,715,251	126,884,881	143,312,746
Convertible notes outstanding [Member]
Schedule of Weighted Average Diluted Shares [Line Items]
Weighted average diluted shares	124,343	293,973	365,463
Convertible preferred stock outstanding [Member]
Schedule of Weighted Average Diluted Shares [Line Items]
Weighted average diluted shares	39,090,908	39,090,908	39,447,283
Shares underlying warrants outstanding [Member]
Schedule of Weighted Average Diluted Shares [Line Items]
Weighted average diluted shares	7,500,000	87,500,000	103,500,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details) - Schedule of Fair Value Hierarchy for those Assets and Liabilities - USD ($)	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Fair Value Hierarchy for Assets and Liabilities [Line Items]
Derivative liability	$ 4,352	$ 2,146	$ 6,944	$ 20,442
Total	4,352	2,146
Level 1 [Member]
Schedule of Fair Value Hierarchy for Assets and Liabilities [Line Items]
Derivative liability
Total
Level 2 [Member]
Schedule of Fair Value Hierarchy for Assets and Liabilities [Line Items]
Derivative liability
Total
Level 3 [Member]
Schedule of Fair Value Hierarchy for Assets and Liabilities [Line Items]
Derivative liability	4,352	2,146
Total	$ 4,352	$ 2,146

Revenue Recognition (Details) -

Revenue Recognition (Details) - Schedule of Revenue by Product Category - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Schedule of Revenue by Product Category [Line Items]
Total revenue	$ 793,329	$ 361,359	$ 1,610,363	$ 1,147,557	$ 2,409,953	$ 1,530,223
Training [Member]
Schedule of Revenue by Product Category [Line Items]
Total revenue			267,827	291,464	599,425	279,404
Product supplies [Member]
Schedule of Revenue by Product Category [Line Items]
Total revenue			769,237	629,456	1,329,159	866,104
Equipment [Member]
Schedule of Revenue by Product Category [Line Items]
Total revenue			102,060	109,740	162,370	163,460
Patient procedures [Member]
Schedule of Revenue by Product Category [Line Items]
Total revenue			$ 471,259	$ 116,897	$ 318,999	$ 221,255

Revenue Recognition (Details)_2

Revenue Recognition (Details) - Schedule of Revenues, Cost of Revenues, Gross Profits, Assets and Net Profit (Loss) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Schedule of Revenues, Cost of Revenues, Gross Profits, Assets and Net Profit (Loss) [Line Items]
Revenue			$ 1,639,863		$ 2,409,953
Cost of revenue	$ 266,445	$ 107,535	514,488	$ 356,932	734,285	$ 653,256
Gross profit			$ 1,125,375		$ 1,675,668
Gross Profit %			68.63%		69.53%
Assets	3,079,586		$ 3,079,586		$ 2,879,103
Net profit (loss)	(2,076,620)	$ (2,030,223)	(4,037,640)	$ (3,700,470)	(9,813,666)	$ (5,506,822)
Global Stem Cells Group [Member]
Schedule of Revenues, Cost of Revenues, Gross Profits, Assets and Net Profit (Loss) [Line Items]
Revenue			1,610,363		2,409,953
Cost of revenue			514,488		734,285
Gross profit			$ 1,095,875		$ 1,675,668
Gross Profit %			68.05%		69.53%
Assets	1,168,726		$ 1,168,726		$ 908,171
Net profit (loss)			(104,647)		(323,109)
Meso Numismatics [Member]
Schedule of Revenues, Cost of Revenues, Gross Profits, Assets and Net Profit (Loss) [Line Items]
Revenue
Cost of revenue
Gross profit
Gross Profit %			0%		0%
Assets	$ 1,910,860		$ 1,910,860		$ 1,970,932
Net profit (loss)			$ (3,932,993)		$ (9,490,557)

Notes Payable (Details)

Notes Payable (Details) - USD ($)													6 Months Ended	12 Months Ended
	Nov. 20, 2023	Dec. 30, 2021	Sep. 20, 2021	Aug. 18, 2021	Jun. 22, 2021	Jan. 06, 2021	Dec. 31, 2020	Dec. 09, 2020	Dec. 07, 2020	Dec. 31, 2019	Dec. 03, 2019	Aug. 04, 2017	Jun. 30, 2024	Dec. 31, 2023		Dec. 31, 2022	Dec. 31, 2020	Nov. 25, 2019	Jan. 08, 2019	Dec. 31, 2015
Notes Payable [Line Items]
Price per share (in Dollars per share)																		$ 1.2
Aggregate amount										$ 97,252
Company payments													$ 0	$ 9,850		$ 15,000
Debt discount amortization expense													4,958	7,679
Outstanding convertible notes													$ 0	$ 9,850		15,000
Maturity date		17 months	3 years		3 years	1 year		2 years										4 years
Premium Interest percentage																		20%
Default penalty									$ 5,379,624
Cashless warrants purchased (in Shares)			7,500,000		70,000,000	10,000,000		1,000,000	15,000,000
Aggregate principal amount	$ 1,999,999								$ 5,379,624
Promissory note bear interest	6%							15%	15%
Exercise price per shares (in Dollars per share)			$ 0.085			$ 0.03
Warrants issued (in Shares)			7,500,000		70,000,000		1,000,000						10,000,000	10,000,000			1,000,000
Debt amount			$ 360,607		$ 5,465,726		$ 17,491						$ 237,811	$ 237,811			$ 262,376
Secured note exchange	$ 2,506,827
Aggregate consideration	300,000
Outstanding loan													1,999,999	1,999,999
Promissory debentures lender amount		$ 84,000	1,100,000		11,600,000	$ 1,000,000		$ 110,000
Lender had advanced			1,000,000		10,500,000	900,000		100,000
Net of discount			$ 100,000		$ 1,100,000	$ 100,000		$ 10,000
Annual interest rate			12%		12%	15%
Exercise price per shares (in Dollars per share)			$ 0.085		$ 0.1	$ 0.03			$ 0.03
Original loan amount				$ 20,991
Interest rate				8.99%
Interest monthly payments				$ 504.94
Accrued interest		$ 22,162
Premium percent		5%
Premium earned amount		$ 111,470
Bear interest rate		12%
Outstanding loans													7,958	7,958		7,958
Unamortized discount													0	0		139
Interest expenses													2,051,259	3,049,999
Amortization expense													1,511,297
Outstanding promissory notes payable													19,730,731	19,730,731		20,237,559
Premium rate													372,860	2,000	[1]	10,450
Cash payment														300,000		5,776
Amortization expense														3,049,999		1,738,327
Warrant [Member]
Notes Payable [Line Items]
Cashless warrants purchased (in Shares)									15,000,000
Exercise price per shares (in Dollars per share)								$ 0.03	$ 0.03
Exercise price per shares (in Dollars per share)			$ 0.085		$ 0.1	$ 0.033	$ 0.03										$ 0.03
Convertible notes [Member]
Notes Payable [Line Items]
Unpaid interest on convertible notes
Accrued Interest [Member]
Notes Payable [Line Items]
Unpaid interest on convertible notes									$ 5,379,624
Promissory Notes Payable [Member]
Notes Payable [Line Items]
Outstanding convertible notes														1,511,297
Unpaid interest on convertible notes									$ 5,379,624
Outstanding loan														2,872,797		5,379,624
Aggregate promissory notes										332,068
Unamortized discount														0		81,700
Cashless warrants purchased (in Shares)									15,000,000
maturity date													Nov. 23, 2023
Interest rate				20%
Interest expense														3,244,361		2,898,155
Lender Two [Member]
Notes Payable [Line Items]
Outstanding loan													$ 2,872,797	2,872,797
Unamortized discount													0	0
Promissory Debentures [Member]
Notes Payable [Line Items]
Outstanding loan													110,000	110,000		110,000
Unamortized discount													0	0		8,611
Promissory Debentures [Member] | Warrant [Member]
Notes Payable [Line Items]
Outstanding loan													1,000,000	1,000,000		1,000,000
Unamortized discount													0	0		0
Promissory Debentures Two [Member]
Notes Payable [Line Items]
Outstanding loan													11,600,000	11,600,000		11,600,000
Unamortized discount													0	1,927,351		4,707,853
Promissory Debentures Four [Member]
Notes Payable [Line Items]
Outstanding loan													1,100,000	1,100,000		1,100,000
Unamortized discount													61,489	181,381		350,416
Promissory Debentures Six [Member]
Notes Payable [Line Items]
Outstanding loan													111,470	111,470		111,470
Unamortized discount													0	0		1,950
Stock Purchase Agreement [Member]
Notes Payable [Line Items]
Outstanding loan													0	0		0
Outstanding shares rate				100%
Investor for proceeds				$ 400,000
Revenues percentage				7.75%
Accrued interest													519,640	392,551		205,779
Derivatives Liabilities [Member]
Notes Payable [Line Items]
Unpaid interest on convertible notes									$ 5,379,624
Aggregate promissory notes									$ 5,379,624
Cashless warrants purchased (in Shares)									15,000,000
Shares exchanged principal									$ 5,379,624
Digital Arts Media Network [Member]
Notes Payable [Line Items]
Price per share (in Dollars per share)																		$ 1.2
promissory note bear interest																				10%
Maturity date																				1 year
Outstanding loan													130,025	130,025		130,025
Accrued interest													112,050	105,602		92,600
Global Stem Cell Group, Inc [Member]
Notes Payable [Line Items]
Outstanding shares rate				100%
Benito Novas [Member]
Notes Payable [Line Items]
Acquired amount																			$ 45,000
2020 Secured Note [Member]
Notes Payable [Line Items]
Secured note exchange	2,506,827												1,533,042	3,244,361
Aggregate consideration	$ 300,000												0	300,000
Short-Term Investments [Member] | Stock Purchase Agreement [Member]
Notes Payable [Line Items]
Outstanding loan													400,000	400,000		400,000
Promissory Notes Payable [Member]
Notes Payable [Line Items]
Aggregate promissory notes										$ 332,068
Cashless warrants purchased (in Shares)									15,000,000
Warrants issued (in Shares)							15,000,000										15,000,000
Debt amount																	$ 17,491
Interest rate				20%
Promissory Notes Payable [Member] | Promissory Debentures [Member]
Notes Payable [Line Items]
Maturity date		17 months
Promissory debentures lender amount		$ 6,000
Accrued interest		$ 1,578
Premium percent		5%
Premium earned amount		$ 7,958
Bear interest rate		12%
Premium rate		$ 7,958
Convertible Notes Payable [Member]
Notes Payable [Line Items]
Debt discount amortization expense														9,917		18,437
Unamortized discount																19,833
Accrued interest													8,130,463	6,597,422		4,657,529
Chief Executive Officer [Member]
Notes Payable [Line Items]
Converted shares (in Shares)											18,500
Common stock (in Shares)											250,999
Chief Executive Officer [Member] | Business Combination [Member]
Notes Payable [Line Items]
Share issuance of common stock (in Shares)											25,000
Chief Executive Officer [Member] | Related Party [Member]
Notes Payable [Line Items]
Promissory note related party													7,800	7,800		7,800
Series BB Preferred Stock [Member]
Notes Payable [Line Items]
Aggregate shares amount (in Shares)										81,043		25,000
Outstanding loan													398,482	398,482
Shares exchange (in Shares)										276,723	6,500
Unamortized discount													$ 4,017	8,033
Series BB Preferred Stock [Member] | Promissory Notes Payable [Member]
Notes Payable [Line Items]
Outstanding loan														398,482		398,482
Unamortized discount														$ 8,033		$ 16,083
Series BB Preferred Stock [Member] | Promissory Notes Payable [Member]
Notes Payable [Line Items]
Aggregate shares amount (in Shares)										276,723
Series BB Preferred Stock [Member] | Mr Melvin Pereira [Member]
Notes Payable [Line Items]
Shares exchange (in Shares)											6,500
Series BB Preferred Stock [Member] | Business Combination [Member]
Notes Payable [Line Items]
Percentage of acquire											100%
[1] Derived from audited information

Notes Payable (Details) - Sched

Notes Payable (Details) - Schedule of Convertible Notes - Convertible Notes [Member] - USD ($)	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Convertible Notes [Line Items]
Convertible notes payable	$ 44,939	$ 57,252	$ 57,252
Less: Discount	(4,958)	(9,916)
Convertible notes payable, net	$ 39,981	$ 35,023	$ 37,419

Notes Payable (Details) - Sch_2

Notes Payable (Details) - Schedule of Promissory Notes - USD ($)	3 Months Ended	6 Months Ended	12 Months Ended
	Dec. 31, 2023	Jun. 30, 2024	Dec. 31, 2022
Schedule of Promissory Notes [Abstract]
Promissory notes payable	$ 19,722,931	$ 19,722,931	$ 20,237,559
Promissory notes payable-related party	7,800	7,800	49,132
Less: Discount	(2,100,966)	(65,506)	(5,117,631)
Less: Deferred finance costs	(15,798)
Promissory notes payable, net	$ 17,613,966	$ 19,665,225	$ 15,070,796

Notes Payable (Details) - Sch_3

Notes Payable (Details) - Schedule of Fair Values of the Embedded Convertible Notes Derivatives and Tainted Convertible Notes Using the Lattice Valuation - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Schedule of Fair Values of the Embedded Convertible Notes Derivatives and Tainted Convertible Notes Using the Lattice Valuation [Abstract]
Common stock issuable (in Shares)	124,343	293,973
Market value of common stock on measurement date (in Dollars per share)	$ 0.035	$ 0.0073
Adjusted exercise price (in Dollars per share)	$ 0.06	$ 0.06
Risk free interest rate	5.01%
Instrument lives in years	6 months	1 year
Expected volatility	99.80%	83%
Expected dividend yields

Notes Payable (Details) - Sch_4

Notes Payable (Details) - Schedule of Fair Value of the Derivative Liability - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Fair Value of the Derivative Liability [Abstract]
Balance	$ 2,146	$ 6,944
Additions
Fair value loss	2,206	(3,450)	(10,856)
Conversions		(1,348)	2,642
Balance	$ 4,352	$ 2,146	$ 6,944

Stockholders Equity (Details)

Stockholders Equity (Details) - USD ($)															3 Months Ended	6 Months Ended	12 Months Ended
	Dec. 08, 2023	Nov. 30, 2022	Nov. 25, 2022	May 05, 2022	Mar. 23, 2022	Feb. 18, 2022	Jan. 01, 2022	Sep. 20, 2021	Aug. 18, 2021	Jul. 02, 2021	Jun. 22, 2021	Jan. 06, 2021	Dec. 31, 2019	Aug. 04, 2017	Mar. 31, 2021	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 07, 2020	Jun. 26, 2020	Dec. 03, 2019	Nov. 26, 2019	Mar. 29, 2017	Mar. 31, 2016	Jul. 31, 2015	Jun. 30, 2015	Jun. 30, 2014	May 02, 2014
Stockholders Equity [Line Items]
Common stock issued for consulting services (in Dollars)																	$ 455	$ 30,000
Exercise price per warrant (in Dollars per share)								$ 0.085			$ 0.1	$ 0.03									$ 0.03
Warrants expire year											5 years
Issuance of warrants								7,500,000			70,000,000	10,000,000								16,000,000
Warrants issued for debt (in Dollars)								$ 360,607			$ 5,465,726	$ 237,811
Risk free interest rate																	4.75%
Expected life																6 months	1 year
Expected dividend rate
Expected volatility																99.80%	83%
Risk free interest rate minimum																5.01%
Conversion shares																1,000	1,000
Common stock conversion price (in Dollars per share)																$ 0.8	$ 0.8
Monthly based annual rate (in Dollars)							$ 90,000
Other expenses (in Dollars)																$ 503,552	$ 503,552
Stock Issued During Period, Shares, Stock Splits						448	896		448
Warrant [Member]
Stockholders Equity [Line Items]
Shares issued								7,500,000			70,000,000	10,000,000								16,000,000
Exercise price per warrant (in Dollars per share)								$ 0.085			$ 0.1	$ 0.033								$ 0.03
Warrants expire year								3 years			3 years	3 years								3 years
Issuance of warrants											70,000,000	10,000,000
Warrants issued for debt (in Dollars)																				$ 279,867
Risk free interest rate																				0.20%
Expected life																			3 years	3 years
Expected dividend rate																			0%	0%
Expected volatility																				411.72%
Risk free interest rate minimum																			0.20%
Risk free interest rate maximum																			0.45%
Volatility minimum																			338.36%
Volatility maximum																			394.78%
Minimum,[Member]
Stockholders Equity [Line Items]
Shares authorized																										1,500,000,000	500,000,000	200,000,000
Minimum,[Member] | Warrant [Member]
Stockholders Equity [Line Items]
Volatility minimum																			338.36%
Maximum [Member]
Stockholders Equity [Line Items]
Shares authorized																										6,500,000,000	1,500,000,000	500,000,000
Maximum [Member] | Warrant [Member]
Stockholders Equity [Line Items]
Volatility maximum																			394.78%
Two Thousand Twenty Three Transactions [Member]
Stockholders Equity [Line Items]
Share issued for consulting services	50,000
Common stock issued for consulting services (in Dollars)	$ 455
Common stock,shares issued																12,493,938	12,493,938	12,443,938
Common stock,shares outstanding																12,493,938	12,493,938	12,443,938
Two Thousand Twenty Two Transactions [Member]
Stockholders Equity [Line Items]
Share issued for consulting services		193,050		89,485	76,278
Common stock issued for consulting services (in Dollars)		$ 10,000		$ 10,000	$ 10,000
Series of Individually Immaterial Business Acquisitions [Member]
Stockholders Equity [Line Items]
Purchase price (in Dollars)										$ 50,000
Series of Individually Immaterial Business Acquisitions [Member] | Series AA Super Voting Preferred Stock [Member]
Stockholders Equity [Line Items]
Purchase price (in Dollars)										50,000
Series of Individually Immaterial Business Acquisitions [Member] | Series DD Convertible Preferred Stock [Member]
Stockholders Equity [Line Items]
Purchase price (in Dollars)									$ 225,000	$ 50,000
Series AA Super Voting Preferred Stock [Member]
Stockholders Equity [Line Items]
Preferred shares issued																50,000	50,000												11,000,000	1,000,000
Preferred stock, par value (in Dollars per share)																													$ 0.001	$ 0.001
Shares issued																														1
Aggregate vote percentage																67%	67%
Increase in authorized shares																								1,050,000
Repurchase of shares																						1,000,000
Aggregate purchase price (in Dollars)																						$ 160,000
Preferred stock value (in Dollars)																$ 166,795
Votes per preferred share																10,000	10,000
Common stock, voting rights																one	one
Averages transactions percentage																30%	30%
Preferred stock value																	166,795
Series AA Super Voting Preferred Stock [Member] | Benito Novas [Member]
Stockholders Equity [Line Items]
Preferred shares issued										1,000,000						1,000,000
Series AA Super Voting Preferred Stock [Member] | Current Director and President [Member]
Stockholders Equity [Line Items]
Shares issued																						50,000
Series AA Preferred Stock [Member]
Stockholders Equity [Line Items]
Preferred shares issued																1,050,000	1,050,000	1,050,000
Preferred shares outstanding																1,050,000	1,050,000	1,050,000
Aggregate value (in Dollars)																$ 964,000	$ 964,000
Series AA Preferred Stock [Member] | Benito Novas [Member]
Stockholders Equity [Line Items]
Preferred stock value (in Dollars)										$ 963,866						$ 963,866
Series AA Preferred Stock [Member] | Series of Individually Immaterial Business Acquisitions [Member]
Stockholders Equity [Line Items]
Number of shares issued									1,000,000
Series AA Preferred Stock [Member] | Series of Individually Immaterial Business Acquisitions [Member] | Series AA Super Voting Preferred Stock [Member]
Stockholders Equity [Line Items]
Number of shares issued									1,000,000
Series AA Preferred Stock [Member] | Series of Individually Immaterial Business Acquisitions [Member] | Series DD Convertible Preferred Stock [Member]
Stockholders Equity [Line Items]
Number of shares issued									1,000,000
Series DD Preferred Stock [Member]
Stockholders Equity [Line Items]
Shares issued						448										896
Aggregate value (in Dollars)																$ 5,040,000	$ 5,040,000
Number of shares issued																8,974	8,974
Stock Issued During Period, Shares, Stock Splits						448											896
Series DD Preferred Stock [Member] | Series of Individually Immaterial Business Acquisitions [Member]
Stockholders Equity [Line Items]
Number of shares issued									8,974
Purchase price (in Dollars)									$ 225,000
Series DD Preferred Stock [Member] | Series of Individually Immaterial Business Acquisitions [Member] | Series AA Super Voting Preferred Stock [Member]
Stockholders Equity [Line Items]
Number of shares issued									8,974
Purchase price (in Dollars)									$ 225,000
Series BB Preferred Stock [Member]
Stockholders Equity [Line Items]
Preferred stock, par value (in Dollars per share)																									$ 0.001
Preferred shares outstanding													276,723										6,500
Preferred stock, shares authorized																									1,000,000
Liquidation value per share (in Dollars per share)																$ 1
Number of shares issued													81,043	25,000
Returned and cancelled															279,146
Preferred stock liquidation value (in Dollars)																	$ 1
Series BB Preferred Stock [Member] | Convertible Debt [Member]
Stockholders Equity [Line Items]
Shares issued													81,043
Aggregate value (in Dollars)													$ 97,252
Number of shares issued													276,723
Series BB Preferred Stock [Member] | Promissory Notes Payable [Member]
Stockholders Equity [Line Items]
Aggregate value (in Dollars)													$ 332,068
Number of shares issued													276,723
Returned and cancelled													78,620
Number of share outstanding																				279,146
Designation of Series CC Preferred Stock [Member]
Stockholders Equity [Line Items]
Preferred stock, par value (in Dollars per share)			$ 1,000														$ 1,000
Conversion shares			1,000														1,000
Common stock conversion price (in Dollars per share)			$ 0.8														$ 0.8
Series DD Convertible Preferred Stock [Member]
Stockholders Equity [Line Items]
Preferred shares issued																9,870	9,870	9,422
Preferred stock, par value (in Dollars per share)																								$ 0.001
Preferred shares outstanding																9,870	9,870	9,422
Preferred stock, shares authorized																								10,000
Aggregate value (in Dollars)																$ 503,072	$ 503,072
Number of shares issued																896	896		448
Common stock conversion price (in Dollars per share)																$ 3.17	$ 3.17
Consideration paid (in Dollars)																			$ 251,536
Series DD Convertible Preferred Stock [Member] | Global Stem Cell Group, Inc [Member]
Stockholders Equity [Line Items]
Number of shares issued																8,974	8,974
Consideration paid (in Dollars)																$ 5,038,576	$ 5,038,576
Series DD Convertible Preferred Stock [Member] | Benito Novas [Member]
Stockholders Equity [Line Items]
Aggregate value (in Dollars)																$ 5,038,576	$ 5,038,576
Number of shares issued																8,974	8,974
Common stock conversion price (in Dollars per share)																$ 3.17	$ 3.17
Designation of Series DD Convertible Preferred Stock [Member]
Stockholders Equity [Line Items]
Common stock conversion price (in Dollars per share)																$ 3.17	$ 3.17
Preferred Series DD Stock [Member]
Stockholders Equity [Line Items]
Shares issued									448
Stock Issued During Period, Shares, Stock Splits									448
Preferred Series DD Stock [Member] | Series of Individually Immaterial Business Acquisitions [Member] | Series DD Convertible Preferred Stock [Member]
Stockholders Equity [Line Items]
Number of shares issued									8,974

Stockholders Equity (Details) -

Stockholders Equity (Details) - Schedule of Warrant Transactions - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Schedule of Warrant Transactions [Line Items]
Number of Shares Underlying Warrants, Outstanding Beginning balance	87,500,000	103,500,000
Weighted Average Exercise Price, Outstanding Beginning balance	$ 0.091	$ 0.082
Number of Shares Underlying Warrants, Granted
Weighted Average Exercise Price, Granted
Number of Shares Underlying Warrants, Exercised
Weighted Average Exercise Price, Exercised
Number of Shares Underlying Warrants, Expired	(80,000,000)	(16,000,000)
Weighted Average Exercise Price, Expired	$ (0.092)	$ (0.03)
Number of Shares Underlying Warrants, Outstanding Ending balance	7,500,000	87,500,000
Weighted Average Exercise Price, Outstanding Ending balance	$ 0.091	$ 0.091

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)					6 Months Ended		12 Months Ended
	Feb. 18, 2022	Jan. 01, 2022	Aug. 18, 2021	Jan. 08, 2019	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Related Party Transactions [Line Items]
Monthly based annual rate		$ 90,000
Stock splits (in Shares)	448	896	448
Consulting services						$ 133,470
Percentage of stock purchase agreement			100%
Enterprise Technology Consulting [Member]
Related Party Transactions [Line Items]
Company owned percentage					100%		100%
Stock Purchase Agreement [Member]
Related Party Transactions [Line Items]
Percentage of stock purchase agreement			100%
Original loan amount				$ 20,991
Loan amount interest term				48 years
Monthly payments				$ 504.94
Outstanding auto loan					$ 0		$ 0	$ 0
Stock Purchase Agreement [Member] | Loan [Member]
Related Party Transactions [Line Items]
Loan amount interest term				48 months
Benito Novas [Member]
Related Party Transactions [Line Items]
Consulting services							233,893	200,390
Benito Novas [Member] | Stock Purchase Agreement [Member]
Related Party Transactions [Line Items]
Related auto loan				$ 45,000
Benito Novas [Member]
Related Party Transactions [Line Items]
Consulting services					122,107
Benito Novas [Member] | Stock Purchase Agreement [Member]
Related Party Transactions [Line Items]
Related auto loan				$ 45,000
Interest				8.99%
Chief Executive Officer [Member]
Related Party Transactions [Line Items]
Consulting services					$ 45,000		$ 90,000	$ 90,000

Commitments and Contingencies (

Commitments and Contingencies (Details)	6 Months Ended		12 Months Ended
	Jun. 30, 2024 USD ($) m²	Jun. 30, 2023 USD ($)	Dec. 31, 2023 USD ($) m²	Dec. 31, 2022 USD ($)
Commitments and Contingencies [Line Items]
Percentage of asset disposition payment	27.50%		27.50%
Area of land held (in Square Meters) | m²	1,647		1,647
Monthly rent	$ 2,714		$ 2,714
Security deposit	5,588		5,588
Monthly rent	$ 40,981	$ 22,744	$ 53,451	$ 44,097
Global Stem Cell Group [Member]
Commitments and Contingencies [Line Items]
Area of land held (in Square Meters) | m²	1,216
Tulum Trade Center [Member]
Commitments and Contingencies [Line Items]
Area of land held (in Square Meters) | m²	2,863
Monthly rent	$ 6,341
Security deposit	$ 11,725

Property and Equipment, Net (De

Property and Equipment, Net (Details) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Property and Equipment, Net [Abstract]
Depreciation expense	$ 110,773	$ 65,733	$ 212,562	$ 55,199

Property and Equipment, Net (_2

Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net - USD ($)	Jun. 30, 2024	Dec. 31, 2023		Dec. 31, 2022
Schedule of Property and Equipment, Net [Line Items]
Less: accumulated depreciation	$ (419,470)	$ (308,697)		$ (96,135)
Total property and equipment, net	360,341	359,303	[1]	186,269
Computer, equipment and vehicles [Member]
Schedule of Property and Equipment, Net [Line Items]
Property and equipment, gross	170,302	166,774
Leasehold Improvements [Member]
Schedule of Property and Equipment, Net [Line Items]
Property and equipment, gross	$ 609,509	$ 501,226		$ 133,208
[1] Derived from audited information

Property and Equipment, Net (_3

Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net (Parentheticals)	Jun. 30, 2024
Maximum [Member]
Schedule of Property and Equipment, Net [Line Items]
Estimated useful life	5 years
Minimum [Member]
Schedule of Property and Equipment, Net [Line Items]
Estimated useful life	2 years

Intellectual Property (Details)

Intellectual Property (Details) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Intellectual Property [Abstract]
Amortization expense intellectual property	$ 48,770	$ 48,770	$ 97,540	$ 97,540
Estimated useful lives	5 years		5 years

Intellectual Property (Detail_2

Intellectual Property (Details) - Schedule of Fair Value of the Intangible Assets - USD ($)	Jun. 30, 2024	Dec. 31, 2023		Dec. 31, 2022
Schedule of Fair Value of the Intangible Assets [Line Items]
Intangible assets	$ 487,700	$ 487,700		$ 487,700
Less: accumulated amortization	(279,926)	(231,156)		(133,616)
Total intangible assets, net	207,774	256,544	[1]	354,084
Tradename - Trademarks [Member]
Schedule of Fair Value of the Intangible Assets [Line Items]
Intangible assets	87,700	87,700		87,700
Intellectual Property / Licenses [Member]
Schedule of Fair Value of the Intangible Assets [Line Items]
Intangible assets	363,000	363,000
Customer Base [Member]
Schedule of Fair Value of the Intangible Assets [Line Items]
Intangible assets	$ 37,000	$ 37,000		$ 37,000
[1] Derived from audited information

Operating Leases (Details)

Operating Leases (Details)	6 Months Ended	12 Months Ended
	Jun. 30, 2024 USD ($) ft²	Dec. 31, 2023 USD ($) ft²
Operating Leases [Line Items]
Monthly rent	$ 2,714	$ 2,714
Security deposit	$ 5,588	$ 5,588
Tulum Trade Center [Member]
Operating Leases [Line Items]
Square feet of area (in Square Feet) | ft²	2,863
Monthly rent	$ 6,341
HELLIMEX, S.A. [Member]
Operating Leases [Line Items]
Square feet of area (in Square Feet) | ft²	1,647	1,647
Global Stem Cell Group, Inc. [Member]
Operating Leases [Line Items]
Square feet of area (in Square Feet) | ft²	1,216
Security deposit	$ 11,725
Tulum Trade Center [Member]
Operating Leases [Line Items]
Monthly rent	$ 6,341

Operating Leases (Details) - Sc

Operating Leases (Details) - Schedule of Undiscounted Cash Payment Obligations for its Non-Cancelable Lease Liabilities - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Schedule of Undiscounted Cash Payment Obligations for its Non-Cancelable Lease Liabilities [Abstract]
2024	$ 38,046
2025	76,092	$ 2,714
2026
2027
2028
Total undiscounted cash payments	114,138	2,714
Less interest	(5,980)
Present value of payments	$ 108,158	$ 2,714

Goodwill (Details)

Goodwill (Details) - USD ($)		6 Months Ended	12 Months Ended
	Aug. 18, 2021	Jun. 30, 2024	Dec. 31, 2023		Dec. 31, 2022	Dec. 31, 2021
Goodwill [Line Items]
Stock purchase percentage	100%
Cash	$ 225,000		$ 175,000
Purchase price		$ 6,229,000	6,229,000
Impairment of goodwill		4,125,460	4,125,460
Goodwill		1,679,978	1,679,978	[1]	$ 5,805,438	$ 5,805,438
Stock Purchase Agreement [Member]
Goodwill [Line Items]
Cash		225,000	225,000
Series AA Preferred Stock [Member]
Goodwill [Line Items]
Aggregate value		$ 964,000	964,000
Series AA Preferred Stock [Member] | Series of Individually Immaterial Business Acquisitions [Member]
Goodwill [Line Items]
Number of shares issued (in Shares)	1,000,000
Series AA Preferred Stock [Member] | Stock Purchase Agreement [Member]
Goodwill [Line Items]
Number of shares issued (in Shares)		1,000,000
Aggregate value			$ 1,000,000
Series DD Preferred Stock [Member]
Goodwill [Line Items]
Cash		$ 175,000
Number of shares issued (in Shares)		8,974	8,974
Aggregate value		$ 5,040,000	$ 5,040,000
Series DD Preferred Stock [Member] | Series of Individually Immaterial Business Acquisitions [Member]
Goodwill [Line Items]
Number of shares issued (in Shares)	8,974
[1] Derived from audited information

Goodwill (Details) - Schedule o

Goodwill (Details) - Schedule of Goodwill - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2024		Dec. 31, 2023		Dec. 31, 2022
Schedule of Goodwill [Abstract]
Balance beginning	$ 1,679,978	[1]	$ 5,805,438		$ 5,805,438
Acquisition
Impairment			(4,125,460)
Balance ending	$ 1,679,978		$ 1,679,978	[1]	$ 5,805,438
[1] Derived from audited information

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Subsequent Events [Line Items]
Security deposit	$ 5,588	$ 5,588
Global Stem Cell Group, Inc [Member]
Subsequent Events [Line Items]
Rent		6,341
Security deposit		$ 11,725
Series BB Preferred Stock [Member] | Subsequent Event [Member]
Subsequent Events [Line Items]
Shares of preferred stock		1,000,000
Series CC Preferred Stock [Member] | Subsequent Event [Member]
Subsequent Events [Line Items]
Shares of preferred stock		8,000,000

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details) - Schedule of Weighted Average Diluted Shares - shares	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Weighted Average Diluted Shares [Line Items]
Anti dilutive	46,715,251	126,884,881	143,312,746
Convertible Notes Outstanding [Member]
Schedule of Weighted Average Diluted Shares [Line Items]
Anti dilutive	124,343	293,973	365,463
Convertible Preferred Stock Outstanding [Member]
Schedule of Weighted Average Diluted Shares [Line Items]
Anti dilutive	39,090,908	39,090,908	39,447,283
Shares Underlying Warrants Outstanding [Member]
Schedule of Weighted Average Diluted Shares [Line Items]
Anti dilutive	7,500,000	87,500,000	103,500,000

Summary of Significant Accoun_7

Summary of Significant Accounting Policies (Details) - Schedule of Fair Value Hierarchy for those Assets and Liabilities - USD ($)	Jun. 30, 2024	Dec. 31, 2023		Dec. 31, 2022
Schedule of Fair Value Hierarchy for Assets and Liabilities [Line Items]
Derivative liability	$ 4,352	$ 2,146	[1]	$ 6,944
Total		2,146		6,944
Level 1 [Member]
Schedule of Fair Value Hierarchy for Assets and Liabilities [Line Items]
Derivative liability
Total
Level 2 [Member]
Schedule of Fair Value Hierarchy for Assets and Liabilities [Line Items]
Derivative liability
Total
Level 3 [Member]
Schedule of Fair Value Hierarchy for Assets and Liabilities [Line Items]
Derivative liability		2,146		6,944
Total		$ 2,146		$ 6,944
[1] Derived from audited information

Revenue Recognition (Details)_3

Revenue Recognition (Details) - Schedule of Revenue by Product Category - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Schedule of Revenue by Product Category [Line Items]
Total revenue	$ 793,329	$ 361,359	$ 1,610,363	$ 1,147,557	$ 2,409,953	$ 1,530,223
Training [Member]
Schedule of Revenue by Product Category [Line Items]
Total revenue			267,827	291,464	599,425	279,404
Product Supplies [Member]
Schedule of Revenue by Product Category [Line Items]
Total revenue			769,237	629,456	1,329,159	866,104
Equipment [Member]
Schedule of Revenue by Product Category [Line Items]
Total revenue			102,060	109,740	162,370	163,460
Patient procedures [Member]
Schedule of Revenue by Product Category [Line Items]
Total revenue			$ 471,259	$ 116,897	$ 318,999	$ 221,255

Revenue Recognition (Details)_4

Revenue Recognition (Details) - Schedule of Revenues, Cost of Revenues, Gross Profits, Assets and Net Loss - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Schedule of Revenues, Cost of Revenues, Gross Profits, Assets and Net Loss [Line Items]
Revenue			$ 1,639,863		$ 2,409,953
Cost of revenue	$ 266,445	$ 107,535	514,488	$ 356,932	734,285	$ 653,256
Gross profit			$ 1,125,375		$ 1,675,668
Gross Profit %			68.63%		69.53%
Assets	3,079,586		$ 3,079,586		$ 2,879,103
Net loss	(2,076,620)	$ (2,030,223)	(4,037,640)	$ (3,700,470)	(9,813,666)	$ (5,506,822)
Global Stem Cells Group [Member]
Schedule of Revenues, Cost of Revenues, Gross Profits, Assets and Net Loss [Line Items]
Revenue			1,610,363		2,409,953
Cost of revenue			514,488		734,285
Gross profit			$ 1,095,875		$ 1,675,668
Gross Profit %			68.05%		69.53%
Assets	1,168,726		$ 1,168,726		$ 908,171
Net loss			(104,647)		(323,109)
Meso Numismatics [Member]
Schedule of Revenues, Cost of Revenues, Gross Profits, Assets and Net Loss [Line Items]
Revenue
Cost of revenue
Gross profit
Gross Profit %			0%		0%
Assets	$ 1,910,860		$ 1,910,860		$ 1,970,932
Net loss			$ (3,932,993)		$ (9,490,557)

Notes Payable (Details) - Sch_5

Notes Payable (Details) - Schedule of Convertible Notes - Convertible Notes [Member] - USD ($)	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Convertible Notes [Line Items]
Convertible notes payable	$ 44,939	$ 57,252	$ 57,252
Less: Discount			19,833
Convertible notes payable, net	$ 39,981	35,023	$ 37,419
Previously Reported [Member]
Schedule of Convertible Notes [Line Items]
Convertible notes payable		44,939
Less: Discount		9,916
Convertible notes payable, net		$ 35,023

Notes Payable (Details) - Sch_6

Notes Payable (Details) - Schedule of Promissory - USD ($)	3 Months Ended	6 Months Ended	12 Months Ended
	Dec. 31, 2023	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Notes Payable (Details) - Schedule of Promissory [Line Items]
Promissory notes payable	$ 19,722,931	$ 19,722,931		$ 20,237,559
Less: Discount	2,100,966	65,506	$ 2,100,966	5,117,631
Less: Deferred finance costs	7,800	7,800	7,800	49,132
Promissory notes payable, net	17,613,966	$ 19,665,225	17,613,966	$ 15,070,796
Previously Reported [Member]
Notes Payable (Details) - Schedule of Promissory [Line Items]
Promissory notes payable			19,730.731
Less: Discount	2,100,966		2,100,966
Less: Deferred finance costs	15,798		15,798
Promissory notes payable, net	$ 17,613,966		$ 17,613,966

Notes Payable (Details) - Sch_7

Notes Payable (Details) - Schedule of Fair Values of the Embedded Convertible Notes Derivatives and Tainted Convertible Notes Using the Lattice Valuation - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Schedule of Fair Values of the Embedded Convertible Notes Derivatives and Tainted Convertible Notes Using the Lattice Valuation [Abstract]
Common stock issuable (in Shares)	124,343	293,973
Market value of common stock on measurement date (in Dollars per share)	$ 0.035	$ 0.0073
Adjusted exercise price (in Dollars per share)	$ 0.06	$ 0.06
Risk free interest rate		4.75%
Instrument lives in years	6 months	1 year
Expected volatility	99.80%	83%
Expected dividend yields

Notes Payable (Details) - Sch_8

Notes Payable (Details) - Schedule of Fair Value of the Derivative Liability - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Fair Value of the Derivative Liability [Abstract]
Beginning Balance	$ 2,146	$ 6,944	$ 20,442
Additions
Fair value gain (loss)	2,206	(3,450)	(10,856)
Conversions		(1,348)	2,642
Ending Balance	$ 4,352	$ 2,146	$ 6,944

Stockholders Equity (Details)_2

Stockholders Equity (Details) - Schedule of Warrant Transactions - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Number of Warrants [Member]
Schedule of Warrant Transactions [Line Items]
Number of Shares Underlying Warrants, Outstanding Beginning balance	103,500,000	103,500,000
Number of Warrants, Granted
Number of Warrants, Exercised
Number of Warrants, Expired	(16,000,000)
Number of Shares Underlying Warrants, Outstanding Ending balance	87,500,000	103,500,000
Weighted Average Exercise Price [Member]
Schedule of Warrant Transactions [Line Items]
Weighted Average Exercise Price, Outstanding Beginning balance	$ 0.082	$ 0.082
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired	(0.03)
Weighted Average Exercise Price, Outstanding Ending balance	$ 0.091	$ 0.082

Property and Equipment, Net (_4

Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net - USD ($)	Jun. 30, 2024	Dec. 31, 2023		Dec. 31, 2022
Schedule of Property and Equipment, Net [Line Items]
Less: accumulated depreciation	$ (419,470)	$ (308,697)		$ (96,135)
Total property and equipment, net	360,341	359,303	[1]	186,269
Computer and office equipment [Member]
Schedule of Property and Equipment, Net [Line Items]
Property and equipment, gross		166,774		149,196
Leasehold Improvements [Member]
Schedule of Property and Equipment, Net [Line Items]
Property and equipment, gross	$ 609,509	$ 501,226		$ 133,208
[1] Derived from audited information

Property and Equipment, Net (_5

Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net (Parentheticals)	Dec. 31, 2023
Computer and office equipment [Member]
Schedule of Property and Equipment, Net [Line Items]
Estimated useful life	5 years
Leasehold Improvements [Member]
Schedule of Property and Equipment, Net [Line Items]
Estimated useful life	2 years

Intellectual Property (Detail_3

Intellectual Property (Details) - Schedule of Fair Value of the Intangible Assets - USD ($)	Jun. 30, 2024	Dec. 31, 2023		Dec. 31, 2022
Schedule of Fair Value of the Intangible Assets [Line Items]
Intangible assets	$ 487,700	$ 487,700		$ 487,700
Less: accumulated amortization	(279,926)	(231,156)		(133,616)
Total intangible assets, net	207,774	256,544	[1]	354,084
Tradename - Trademarks [Member]
Schedule of Fair Value of the Intangible Assets [Line Items]
Intangible assets	87,700	87,700		87,700
Intellectual Property / Licenses [Member]
Schedule of Fair Value of the Intangible Assets [Line Items]
Intangible assets		363,000		363,000
Customer Base [Member]
Schedule of Fair Value of the Intangible Assets [Line Items]
Intangible assets	$ 37,000	$ 37,000		$ 37,000
[1] Derived from audited information

Income Taxes (Details)

Income Taxes (Details)	12 Months Ended
	Dec. 31, 2023
Income Taxes [Abstract]
Federal statutory rate	21%
U.S federal income tax rate, percentage	21%
Net operating loss carry forward	$26,386,980

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedule of Amount Computed Using the U. S Federal Income Tax Rate	12 Months Ended
	Dec. 31, 2023 USD ($)
Schedule of Amount Computed Using the U. S Federal Income Tax Rate [Abstract]
Income tax (benefit)	$ (2,060,870)
Non-deductible	1,190,032
Change in valuation allowance	870,838
Income tax (benefit) per financial statements

Income Taxes (Details) - Sche_2

Income Taxes (Details) - Schedule of Deferred Income Tax Assets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Deferred Tax Assets:
Net operating losses	$ 5,292,725	$ 4,421,887
Less valuation allowance	(5,292,725)	(4,421,887)
Total deferred tax assets

Operating Leases (Details) - _2

Operating Leases (Details) - Schedule of Undiscounted Cash Payment Obligations for its Non-Cancelable Lease Liabilities - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Schedule of Undiscounted Cash Payment Obligations for its Non-Cancelable Lease Liabilities [Abstract]
2024	$ 76,092	$ 2,714
2025
2026
2027
2028
Total undiscounted cash payments	114,138	2,714
Less interest	5,980
Present value of payments	$ 108,158	$ 2,714

Goodwill (Details) - Schedule_2

Goodwill (Details) - Schedule of Goodwill - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2024		Dec. 31, 2023		Dec. 31, 2022
Schedule of Goodwill [Abstract]
Balance beginning	$ 1,679,978	[1]	$ 5,805,438		$ 5,805,438
Acquisition
Impairment			(4,125,460)
Balance ending	$ 1,679,978		$ 1,679,978	[1]	$ 5,805,438
[1] Derived from audited information

Discontinued Operations (Detail

Discontinued Operations (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Oct. 28, 2022
Discontinued Operations [Line Items]
Liabilities outstanding	$ 68,313
Mr Melvin Pereira [Member] | Series of Individually Immaterial Business Acquisitions [Member]
Discontinued Operations [Line Items]
Percentage of acquire		100%

Discontinued Operations (Deta_2

Discontinued Operations (Details) - Schedule of Loss from Discontinued Operations	12 Months Ended
	Dec. 31, 2022 USD ($)
Schedule of Loss from Discontinued Operations [Abstract]
Revenue	$ 24,991
Cost of revenue	23,024
Gross profit	1,967
Operating expenses
Advertising and marketing	117
Depreciation and amortization expense	1,400
General and administrative	(67,864)
Total operating expenses	(66,347)
Gain from discontinued operations	$ 68,313